-- DBMS: bigquery
CREATE TABLE `isb-cgc-bq.pancancer_atlas.Original_clinical_PANCAN_patient_with_followup`
(
  bcr_patient_uuid STRING OPTIONS(description="Patient universally unique identifier, eg 180A2B9C-9CAC-4D96-86E8-CD6B3B9386B5"),
  bcr_patient_barcode STRING OPTIONS(description="TCGA barcode identifier for the study participant, eg TCGA-02-0001"),
  acronym STRING OPTIONS(description="TCGA study abbreviation, eg LAML. Full list available at https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations"),
  gender STRING OPTIONS(description="Participant gender; eg. MALE, FEMALE"),
  vital_status STRING OPTIONS(description="The latest updated vital status from follow-up data, eg Alive, Dead, [Discrepancy], NULL"),
  days_to_birth FLOAT64 OPTIONS(description="Days since birth (a negative value, relative to the date of diagnosis which is considered to be t=0)"),
  days_to_death STRING OPTIONS(description="If vital_status indicates 'dead', then this is the number of days to death (a positive value) relative to the date of diagnosis."),
  days_to_last_followup STRING OPTIONS(description="If vital_status indicates 'alive', then this is the number of days from the date of diagnosis to the last followup (communication contact)."),
  days_to_initial_pathologic_diagnosis INT64 OPTIONS(description="The number of days to initial pathologic diagnosis"),
  age_at_initial_pathologic_diagnosis INT64 OPTIONS(description="Age, in years, at which a condition or disease was first diagnosed"),
  icd_10 STRING OPTIONS(description="Alphanumeric value used to describe the disease code from the tenth version of the International Classification of Disease (ICD-10). Examples: C01, C55, C40.3"),
  tissue_retrospective_collection_indicator STRING OPTIONS(description="Text indicator for the time frame of tissue procurement, indicating that the tissue was obtained and stored prior to the initiation of the project. Takes YES, NO, NULL, and [Discrepancy] values."),
  icd_o_3_histology STRING OPTIONS(description="Code that represents the histology of the disease using the third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms"),
  tissue_prospective_collection_indicator STRING OPTIONS(description="Text indicator for the time frame of tissue procurement, indicating that the tissue was procured in parallel to the project. Takes YES, NO, NULL, and [Discrepancy] values."),
  history_of_neoadjuvant_treatment STRING OPTIONS(description="Possible values: Yes, No,Yes - Pharmaceutical Treatmet Prior to Resection, Yes - Radiation Prior to Resection(also can be blank)"),
  icd_o_3_site STRING OPTIONS(description="Code that represents the site of the disease using the third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms. Examples:C01.9, C20.9, C32.1"),
  tumor_tissue_site STRING OPTIONS(description="Category describing current smoking status and smoking history as self-reported by a participant.; eg. 1, 2, etc."),
  new_tumor_event_after_initial_treatment STRING OPTIONS(description="Indicates whether a patient has had a new tumor event after initial treatment; Yes, No"),
  radiation_therapy STRING OPTIONS(description="Indicates whether a patient has had radiation therapy; YES, NO, NULL, [Unknown], and [Discrepancy]"),
  race STRING OPTIONS(description="The race of a participant, independent from ethnicity; eg. White, Black or African American, Asian, Native Hawaiian or other Pacific Islander, American Indian or Alaska Native"),
  project_code STRING OPTIONS(description="Project code; TCGA or NULL"),
  prior_dx STRING OPTIONS(description="Indicator and type of prior diagnosis; eg. No; Yes, History of Prior Malignancy; Yes, History of Synchronous/Bilateral Malignancy; Both History of Synchronous/Bilateral and Prior Malignancy, [Discrepancy], and NULL"),
  disease_code STRING OPTIONS(description="A code representing the type of cancer. Values can be found at https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations; eg. OV, GBM, LUAD"),
  ethnicity STRING OPTIONS(description="The ethnic origination of a participant, independent from race; eg. Not Hispanic or Latino, Hispanic or Latino"),
  informed_consent_verified STRING OPTIONS(description="Indicates whether informed consent is verified; YES"),
  person_neoplasm_cancer_status STRING OPTIONS(description="The participant's cancer status; Either WITH TUMOR or TUMOR FREE, [Unknown], [Discrepancy], and NULL"),
  patient_id STRING OPTIONS(description="Participant ID; eg. AA2W, AA2T"),
  year_of_initial_pathologic_diagnosis INT64 OPTIONS(description="Four digit year of the initial pathologic diagnosis"),
  histological_type STRING OPTIONS(description="The histological type of cancer; eg. Adenosquamous, Astrocytoma, etc."),
  tissue_source_site STRING OPTIONS(description="Tissue Source Site Codes; eg. FF, 4G. Full list available at https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tissue-source-site-codes"),
  form_completion_date STRING OPTIONS(description="Form completion date; eg. 2013-12-23"),
  pathologic_T STRING OPTIONS(description="The pathologic T score is a rating of the extent of the primary tumor, based on surgery or biopsy; eg. T1, T2, T3, T4"),
  pathologic_M STRING OPTIONS(description="The pathologic M score is a rating of metastasis, that is, how much cancer has spread to distant sites. It is based on surgery or biopsy; eg. MX, M0, M1"),
  clinical_M STRING OPTIONS(description="The clinical M score is a rating of metastasis, that is, how much cancer has spread to distant sites. It is based on results of tests done before surgery, such as physical exams and imaging scans; eg. MX, M0, M1"),
  pathologic_N STRING OPTIONS(description="The pathologic N score is a rating of the extent of cancer within nearby lymph nodes, based on surgery or biopsy; eg. N1, N2, N3"),
  system_version STRING OPTIONS(description="System version; eg. 2009, 4th"),
  pathologic_stage STRING OPTIONS(description="The stage of the cancer, based on surgery or biopsy; eg. Stage II, Stage III, Stage IV, Stage IVA, Stage IIIB, Stage IIIS, Stage IIIC"),
  stage_other STRING OPTIONS(description="Other stages of cancer; this field is NULL for all rows"),
  clinical_stage STRING OPTIONS(description="The stage of the cancer, based on results of tests done before surgery, such as physical exams and imaging scans; eg. Stage I, Stage II, Stage III, Stage IV"),
  clinical_T STRING OPTIONS(description="The clinical T score is a rating of the extent of the primary tumor, based on results of tests done before surgery, such as physical exams and imaging scans; eg. T1, T2, T3, T4"),
  clinical_N STRING OPTIONS(description="The clinical N score is a rating of the extent of cancer within nearby lymph nodes, based on results of tests done before surgery, such as physical exams and imaging scans; eg. N1, N2, N3"),
  extranodal_involvement STRING OPTIONS(description="Indicator that identifies whether a patient with malignant lymphoma has lymphomatous involvement of an extranodal site. YES, NO, [Not Applicable], and NULL"),
  postoperative_rx_tx STRING OPTIONS(description="YES, NO, [Discrepancy], and [Unknown] indicator of post operative residual tumor"),
  primary_therapy_outcome_success STRING OPTIONS(description="Kind of outcome achieved after the completion of the initial course of treatment; eg. Complete Remission/Response, Progressive Disease, Stable Disease, Partial Remission/Response, Persistent Diseaase, etc."),
  lymph_node_examined_count STRING OPTIONS(description="The number of lymph nodes examined. Some records contains [Not Applicable]."),
  primary_lymph_node_presentation_assessment STRING OPTIONS(description="YES, NO, [Discrepancy], and [Unknown] indicator of primary lymph node presentation assessment"),
  initial_pathologic_diagnosis_method STRING OPTIONS(description="Text that describe the initial pathologic diagnosis method, eg. Tumor resection, Excisional Biopsy, Dilation and curettage procedure, etc"),
  number_of_lymphnodes_positive_by_he STRING OPTIONS(description="The number of lymph nodes involved with disease as determined by histological examination"),
  eastern_cancer_oncology_group STRING OPTIONS(description="Eastern cancer oncology group performance status. Integer number between 0 and 5."),
  anatomic_neoplasm_subdivision STRING OPTIONS(description="The spatial location, subdivisions and/or atomic site name of a tumor; eg. Rectum, Larynx, Tonsil, etc."),
  residual_tumor STRING OPTIONS(description="Status of the tissue margin following surgical resection; eg. R0, R1, R2, RX"),
  histological_type_other STRING OPTIONS(description="Additional histological types of cancer; eg. Diffuse sclerosing variant, Ductal/Cribiform, etc."),
  init_pathology_dx_method_other STRING OPTIONS(description="Additional initial pathologic diagnosis methods, eg. Biopsy and endocervical curettage, Cervical biopsies and cystoscopy, etc."),
  karnofsky_performance_score STRING OPTIONS(description="Karnofsky performance score. Describe the classification used of the functional capabilities of a person, values can be 0, 10, 20, ... , 100, [Not Evaluated], or [Unknown]."),
  neoplasm_histologic_grade STRING OPTIONS(description="Rating which expresses the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness; eg. G1, G2, G3, G4, GX, High Grage, GB, Low Grade"),
  height STRING OPTIONS(description="Height of participant in centimeters"),
  weight STRING OPTIONS(description="Weight of participant in kilograms"),
  history_of_radiation_metastatic_site STRING OPTIONS(description="History of radiation metastatic site"),
  days_to_patient_progression_free STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease was formally confirmed as progression-free. Null for all participants."),
  days_to_first_response STRING OPTIONS(description="Number of days between the date used for index and the date of the patient first response to their disease. Null for all participants."),
  days_to_first_partial_response STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease was first confirmed as partial response. Null for all participants."),
  days_to_first_complete_response STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease was first confirmed as compete response. Null for all participants."),
  days_to_tumor_progression STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease progressed. Null for all participants."),
  er_estimated_duration_response STRING OPTIONS(description="Estimated duration response for ER positive tumors. Null for all participants."),
  er_disease_extent_prior_er_treatment STRING OPTIONS(description="Disease extent prior to ER treatment. Null for all participants."),
  er_solid_tumor_response_documented_type STRING OPTIONS(description="Solid tumor response type for ER positive tumors. Null for all participants."),
  er_solid_tumor_response_documented_type_other STRING OPTIONS(description="Additional solid tumor response types for ER positive tumors. Null for all participants."),
  er_response_type STRING OPTIONS(description="Response type for ER positive tumors. Null for all participants."),
  history_of_radiation_primary_site STRING OPTIONS(description="History of radiation in the primary site. Null for all participants."),
  history_prior_surgery_type STRING OPTIONS(description="History prior surgery type. Null for all participants."),
  patient_progression_status STRING OPTIONS(description="Patient progression status. Null for all participants."),
  history_prior_surgery_type_other STRING OPTIONS(description="Additional history prior surgery types. Null for all participants."),
  history_prior_surgery_indicator STRING OPTIONS(description="Indicator of history prior surgery. Null for all participants."),
  field STRING OPTIONS(description="Field. Null for all participants."),
  molecular_abnormality_results_other STRING OPTIONS(description="Additional molecular abnormality results. Null for all participants."),
  molecular_abnormality_results STRING OPTIONS(description="Molecular abnormality results. Null for all participants."),
  number_of_lymphnodes_positive_by_ihc STRING OPTIONS(description="Number of lymph nodes-positive determined by immunohistochemistry"),
  tobacco_smoking_history STRING OPTIONS(description="Description of tobacco skmoking history, eg. Lifelong Non-smoker, Current Reformed Smoker, Duration Not Specified, etc."),
  number_pack_years_smoked STRING OPTIONS(description="A measurement of the amount of smoking exposure an individual has had over time, which is calculated by multiplying the number of cigarettes smoked per day by the number of years smoked, and dividing the product by the number of cigarettes in a pack."),
  stopped_smoking_year STRING OPTIONS(description="Four digit stopped smoking year"),
  performance_status_scale_timing STRING OPTIONS(description="Performance status. Takes values of Post-Adjuvant Therapy, Pre-Adjuvant Therapy, Pre-Operative, Preoperative, Post Adjuvant Therapy, Post Secondary Therapy, or Other"),
  laterality STRING OPTIONS(description="Text term that represents the side of the body on which the tumor or cancer developed."),
  targeted_molecular_therapy STRING OPTIONS(description="The yes/no indicator related to prior administration of cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread. NCI CDE: 3440083"),
  year_of_tobacco_smoking_onset STRING OPTIONS(description="The year in which the participant began smoking."),
  anatomic_neoplasm_subdivision_other STRING OPTIONS(description="Additional spatial location, subdivisions and/or atomic site name of a tumor."),
  patient_death_reason STRING OPTIONS(description="the primary cause of death. NCI CDE: 25"),
  tumor_tissue_site_other STRING OPTIONS(description="Text term that describes another anatomic site location not previously mentioned for the peritumoral tissue. NCI CDE: 5118531"),
  menopause_status STRING OPTIONS(description="The response that describes the menopausal status of a patient (a condition or state relating to the permanent cessation of menses)."),
  age_began_smoking_in_years STRING OPTIONS(description="Age began smoking cigarettes expressed in number of years since birth. NCI CDE: 2178045"),
  margin_status STRING OPTIONS(description="The indication of whether there has been cancer involvement in the surgical margin after tissue removal. NCI CDE: 7038796"),
  kras_gene_analysis_performed STRING OPTIONS(description="Indicator of whether or not analysis for KRAS gene mutation abnormality was performed. NCI CDE: 6060079"),
  kras_mutation_found STRING OPTIONS(description="kras mutation present"),
  death_cause_text STRING OPTIONS(description="The text that describes the cause of death. NCI CDE: 2179658"),
  lactate_dehydrogenase_result STRING OPTIONS(description="Text term to represent the summary result of the medical procedure that involves testing a sample of blood for lactate dehydrogenase (LDH), to help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time. NCI CDE: 3113468"),
  days_to_sample_procurement STRING OPTIONS(description="Days to sample procurement."),
  hbv_test STRING OPTIONS(description="Hepatitis B virus (HBV) test"),
  on_haart_therapy_at_cancer_diagnosis STRING OPTIONS(description="Text term to signify the administration of highly active antiretroviral therapy (HAART) at the time of cancer diagnosis NCI CDE: 2922679"),
  hcv_test STRING OPTIONS(description="The indicator that describes whether or not HCV was performed"),
  prior_aids_conditions STRING OPTIONS(description="Prior AIDS condition."),
  on_haart_therapy_prior_to_cancer_diagnosis STRING OPTIONS(description="Text term to signify the administration of highly active antiretroviral therapy (HAART) before or prior to the time of cancer diagnosis. NCI CDE: 3335156"),
  kshv_hhv8_test STRING OPTIONS(description="Text indicator to respresent whether a serological herpes human virus 8 (HHV8) test was completed for an individual. NCI CDE: 3335774"),
  days_to_hiv_diagnosis STRING OPTIONS(description="Time interval from the date of the initial pathologic diagnosis to the date of human immunodeficiency diagnosis, represented as a calculated number of days. NCI CDE: 4618491"),
  hiv_status STRING OPTIONS(description="the result of a test to detect the presence of human immunodeficiency virus antibody in a patient. NCI CDE: 2180464"),
  hiv_rna_load_at_diagnosis STRING OPTIONS(description="Number to represent the numeric value for a human immunodeficiency virus viral load (the number of HIV viral particles in a sample of blood plasma) assay performed on an individual at the time of diagnosis. NCI CDE: 2922674"),
  cdc_hiv_risk_group STRING OPTIONS(description="The patient risk group category for the Human Immunodeficiency Virus (HIV). NCI CDE: 2542215"),
  history_of_other_malignancy STRING OPTIONS(description="Clinical history of other malignancy."),
  history_immunosuppresive_dx STRING OPTIONS(description="Clinical history of immunosuppresive diagnosis."),
  nadir_cd4_counts STRING OPTIONS(description="A patient's nadir cd4 count."),
  history_relevant_infectious_dx_other STRING OPTIONS(description="History of other relevant infectious diagnosis"),
  history_relevant_infectious_dx STRING OPTIONS(description="History of relevant infectious diagnosis"),
  cd4_counts_at_diagnosis STRING OPTIONS(description="Cd4 counts at diagnosis"),
  history_immunological_disease_other STRING OPTIONS(description="History of other immunological disease."),
  hpv_test STRING OPTIONS(description="The name of the procedure performed to describe the papillomavirus strain being tested. NCI CDE: 6028407"),
  history_immunosuppressive_dx_other STRING OPTIONS(description="Clinical history of other immunosuppresive diagnosis."),
  history_immunological_disease STRING OPTIONS(description="History of immunological disease."),
  lost_follow_up STRING OPTIONS(description="The yes/no/unknown indicator used to describe whether a patient was unable to be contacted or seen for follow-up information. NCI CDE: 6161018"),
  venous_invasion STRING OPTIONS(description="The indication of whether or not there has been extramural invasion of the veins by malignant cells. NCI CDE: 7038780"),
  lymphatic_invasion STRING OPTIONS(description="The indication of whether or not malignant cells are present within lymphatic vessels. NCI CDE: 7038779"),
  perineural_invasion_present STRING OPTIONS(description="The indication of whether or not there is a presence of malignant cells surrounding a nerve. NCI CDE: 7038781"),
  her2_erbb_method_calculation_method_text STRING OPTIONS(description="Text to describe the method used to calculate HER2/ERBB2 positivity in a specimen or sample. NCI CDE: 3087487"),
  her2_immunohistochemistry_level_result STRING OPTIONS(description="The gene that controls cell growth by making the human epidermal growth factor receptor 2, detected by immunohistochemical means and expressed as 0 through 4+. NCI CDE: 2178402"),
  breast_carcinoma_immunohistochemistry_pos_cell_score STRING OPTIONS(description="The score assigned to a breast carcinoma sample on the basis of immunohistochemistry analysis. NCI CDE: 3133874"),
  distant_metastasis_present_ind2 STRING OPTIONS(description="The yes/no indicator whether distant metastases are present."),
  her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text STRING OPTIONS(description="Text to describe the method used to calculate HER2/ERBB2 Fluorescence in situ Hybridization (FISH) positivity in a specimen or sample. NCI CDE: 3087929"),
  breast_carcinoma_immunohistochemistry_progesterone_receptor_pos_finding_scale STRING OPTIONS(description="Text term to specify the immunohistochemistry intensity scale used for a positive finding for progesterone receptor in breast cancer tumor. NCI CDE: 3203083"),
  breast_carcinoma_primary_surgical_procedure_name STRING OPTIONS(description="Text name of a surgical procedure performed for a person with a diagnosis of breast cancer. [Manually-curated]"),
  er_level_cell_percentage_category STRING OPTIONS(description="Classification to represent ER Positive results expressed as a percentage value. NCI CDE: 3128341"),
  breast_carcinoma_progesterone_receptor_status STRING OPTIONS(description="The progesterone receptor status of a primary breast tumor or metastases. NCI CDE: 6117728"),
  breast_carcinoma_surgical_procedure_name STRING OPTIONS(description="Text name of a surgical procedure performed for a person with a diagnosis of breast cancer. [Manually-curated] NCI CDE: 2739580"),
  breast_neoplasm_other_surgical_procedure_descriptive_text STRING OPTIONS(description="Text to describe a surgical procedure performed for a malignant neoplasm of the breast that is different from previously identified options. NCI CDE: 3124493"),
  er_detection_method_text STRING OPTIONS(description="The free-text field to capture the method of measurement used to detect the status of the estrogen receptor. e.g., dextran coated charcoal. NCI CDE: 69"),
  pos_finding_progesterone_receptor_other_measurement_scale_text STRING OPTIONS(description="Text to describe a different scale used to measure progesterone receptor (PR) positivity. NCI CDE: 3086857"),
  her2_erbb_pos_finding_cell_percent_category STRING OPTIONS(description="Classification to represent the number of positive HER2/ERBB2 cells in a specimen or sample. NCI CDE: 3086980"),
  her2_and_centromere_17_positive_finding_other_measurement_scale_text STRING OPTIONS(description="Text to describe a different scale used to measure HER2 and Centromere 17 positivity. NCI CDE: 3087923"),
  pos_finding_metastatic_breast_carcinoma_estrogen_receptor_other_measuremenet_scale_text STRING OPTIONS(description="Text to describe a different scale used to measure metastatic breast carcinoma estrogen receptor (ER) positivity. NCI CDE: 3131877"),
  metastatic_breast_carcinoma_progesterone_receptor_level_cell_percent_category STRING OPTIONS(description="Classification to represent metastatic breast carcinoma Progesterone Receptor (PR) positive results expressed as a percentage value. NCI CDE: 3131891"),
  metastatic_breast_carcinoma_pos_finding_progesterone_receptor_other_measure_scale_text STRING OPTIONS(description="Text to describe a different scale used to measure progesterone receptor (PR) positivity. NCI CDE: 3131992"),
  fluorescence_in_situ_hybridization_diagnostic_procedure_chromosome_17_signal_result_range STRING OPTIONS(description="Result of Chromosone 17 testing, expressed as a range of values. NCI CDE: 3104295"),
  first_recurrent_non_nodal_metastatic_anatomic_site_descriptive_text STRING OPTIONS(description="Text to describe the first non-nodal site of metastatic disease that is different from previously identified choices. NCI CDE: 3124503"),
  first_nonlymph_node_metastasis_anatomic_site STRING OPTIONS(description="Text term to identify the first anatomic site of non-nodal metastatic disease. NCI CDE: 3124499"),
  immunohistochemistry_positive_cell_score STRING OPTIONS(description="The score assigned to a sample on the basis of immunohistochemistry analysis. NCI CDE: 2230166"),
  axillary_lymph_node_stage_method_type STRING OPTIONS(description="The type of technique of staging (assessing the extent of a cancer within the body) of axillary lymph nodes from the area of the armpit. NCI CDE: 2516112"),
  axillary_lymph_node_stage_other_method_descriptive_text STRING OPTIONS(description="Text to describe a technique of staging (assessing the extent of a cancer within the body) from the area of the armpit/axilla that is different from the options previously identified. NCI CDE: 3124496"),
  metastatic_breast_carcinoma_progesterone_receptor_status STRING OPTIONS(description="Text term to represent the overall result of metastatic breast carcinoma Progresterone Receptor (PR) testing. NCI CDE: 3131884"),
  metastatic_breast_carcinoma_immunohistochemistry_pr_pos_cell_score STRING OPTIONS(description="The score assigned to a progesterone receptor positive metastatic breast carcinoma sample on the basis of immunohistochemistry analysis. NCI CDE: 3131988"),
  metastatic_breast_carcinoma_immunohistochemistry_er_pos_cell_score STRING OPTIONS(description="The score assigned to a metastatic breast carcinoma sample on the basis of immunohistochemistry analysis."),
  metastatic_breast_carcinoma_lab_proc_her2_neu_immunohistochemistry_receptor_status STRING OPTIONS(description="Text term to capture the result of medical procedure testing of a sample of metastatic breast carcinoma blood or tissue for HER2 by histochemical localization of immunoreactive substances using labeled antibodies as reagents. NCI CDE: 3131997"),
  metastatic_breast_carcinoma_her2_neu_chromosone_17_signal_ratio_value STRING OPTIONS(description="A numeric value to represesent the measurement of Her2-/neu to chromosone 17 signal in a specimen or sample of metastatic breast carcinoma. NCI CDE: 3132903"),
  surgical_procedure_purpose_other_text STRING OPTIONS(description="Text to capture the reason for a surgical procedure that is different from the purposes previously specified or mentioned. NCI CDE: 2467630"),
  metastatic_breast_carcinoma_her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text STRING OPTIONS(description="Text to describe the method used to calculate HER2/ERBB2 Fluorescence in situ Hybridization (FISH) positivity in a specimen or sample of metastatic breast carcinoma. NCI CDE: 3132910"),
  metastatic_breast_carcinoma_her2_erbb_pos_finding_cell_percent_category STRING OPTIONS(description="Classification to represent the number of positive HER2/ERBB2 cells in a specimen or sample of metastatic breast carcinoma. NCI CDE: 3132322"),
  breast_cancer_surgery_margin_status STRING OPTIONS(description="Text term to describe the pathologic findings of a patient's margins following a breast carcinoma surgical procedure. NCI CDE: 4792338"),
  metastatic_breast_carcinoma_her2_erbb_method_calculation_method_text STRING OPTIONS(description="Text to describe the method used to calculate HER2/ERBB2 positivity in a specimen or sample of metastatic breast carcinoma tissue. NCI CDE: 3132452"),
  breast_carcinoma_estrogen_receptor_status STRING OPTIONS(description="Text term to represent the overall result of Estrogen Receptor (ER) testing. NCI CDE: 2957359"),
  her2_neu_and_centromere_17_copy_number_analysis_input_total_number_count STRING OPTIONS(description="Numeric value to represent the total number of Cells Counted for HER2 & Centromere 17 copy number. NCI CDE: 3087902"),
  pgr_detection_method_text STRING OPTIONS(description="The free-text field to specify the method of measurement used to detect the status of the progesterone receptor (e.g., dextran coated charcoal). NCI CDE: 785"),
  pos_finding_her2_erbb2_other_measurement_scale_text STRING OPTIONS(description="Text to describe a different scale used to measure HER2/ERBB2 positivity. NCI CDE: 3087479"),
  breast_carcinoma_immunohistochemistry_er_pos_finding_scale STRING OPTIONS(description="Text term to specify the immunohistochemistry intensity scale used for a positive finding for estrogen receptor in breast cancer tumor. NCI CDE: 3203081"),
  positive_finding_estrogen_receptor_other_measurement_scale_text STRING OPTIONS(description="Text to describe a different scale used to measure estrogen receptor (ER) positivity. NCI CDE: 3086851"),
  metastatic_breast_carcinoma_erbb2_immunohistochemistry_level_result STRING OPTIONS(description="Result to signify the human epidermal growth factor receptor 2 intensity in a sample of metastatic breast carcinoma, detected by immunohistochemical means and expressed as 0 through 4+. NCI CDE: 3132444"),
  metastatic_breast_carcinoma_pos_finding_other_scale_measurement_text STRING OPTIONS(description="Text to describe a different scale used to measure HER2 and Centromere 17 positivity in a sample or specimen of metastatic breast carcinoma tissue. NCI CDE: 3132907"),
  her2_neu_chromosone_17_signal_ratio_value STRING OPTIONS(description="A numeric value to represent the measurement of Her2-/neu to chromosome 17 signal in a biospecimen. NCI CDE: 2497552"),
  cytokeratin_immunohistochemistry_staining_method_micrometastasis_indicator STRING OPTIONS(description="Text term to identify whether keratin staining techniques were used to visualize the presence of micrometastasis in a tumor specimen. NCI CDE: 3086152"),
  metastatic_breast_carcinoma_estrogen_receptor_detection_method_text STRING OPTIONS(description="The free-text field to capture the method of measurement used to detect the status of the estrogen receptor in a metastatic breast cancer sample. e.g., dextran coated charcoal. NCI CDE: 3131881"),
  metastatic_breast_carcinoma_lab_proc_her2_neu_in_situ_hybridization_outcome_type STRING OPTIONS(description="The type of outcome for HER2 testing in a sample of metastatic breast carcinoma as determined by an in situ hybridization (FISH) assay. NCI CDE: 3132455"),
  metastatic_breast_carcinoma_pos_finding_her2_erbb2_other_measure_scale_text STRING OPTIONS(description="Text to describe a different scale used to measure HER2/ERBB2 positivity in a sample of metastatic breast carcinoma. NCI CDE: 3132448"),
  lab_proc_her2_neu_immunohistochemistry_receptor_status STRING OPTIONS(description="Text term to signify the result of the medical procedure that involves testing a sample of blood or tissue for HER2 by histochemical localization of immunoreactive substances using labeled antibodies as reagents. NCI CDE: 2957563"),
  progesterone_receptor_level_cell_percent_category STRING OPTIONS(description="Classification to represent Progesterone Receptor Positive results expressed as a percentage value. NCI CDE: 3128342"),
  metastatic_breast_carcinoma_estrogen_receptor_level_cell_percent_category STRING OPTIONS(description="Classification to represent metastatic breast carcinoma estrogen receptor (ER) positive results expressed as a percentage value. NCI CDE: 3131869"),
  metastatic_breast_carcinoma_estrogen_receptor_status STRING OPTIONS(description="Text term to represent the overall result of metastatic breast carcinoma Estrogen Receptor (ER) testing. NCI CDE: 3131865"),
  lab_procedure_her2_neu_in_situ_hybrid_outcome_type STRING OPTIONS(description="the type of outcome for HER2 as determined by an in situ hybridization (ISH) assay. NCI CDE: 2854089"),
  her2_neu_breast_carcinoma_copy_analysis_input_total_number STRING OPTIONS(description="Result of HER2 Copy Number testing (for the primary tumor), expressed as a range of values. NCI CDE: 3133738"),
  metastatic_breast_carcinoma_fluorescence_in_situ_hybridization_diagnostic_proc_centromere_17_signal_result_range STRING OPTIONS(description="Result of Centromere 17 testing in a sample or specimen of metastatic breast carcinoma, expressed as a range of values. NCI CDE: 3132887"),
  her2_neu_and_centromere_17_copy_number_metastatic_breast_carcinoma_analysis_input_total_number_count STRING OPTIONS(description="Numeric value to represent the total number of cells counted in a sample of metastatic breast carcinoma for HER2 & Centromere 17 copy number. NCI CDE: 3132899"),
  her2_neu_metastatic_breast_carcinoma_copy_analysis_input_total_number STRING OPTIONS(description="Result of HER2 Copy Number testing (for the metastatic tumor), expressed as a range of values NCI CDE: 3133734"),
  metastatic_breast_carcinoma_progesterone_receptor_detection_method_text STRING OPTIONS(description="The free-text field to specify the method of measurement used to detect the status of the progesterone receptor (PR) in a sample of metastatic breast carcinoma, e.g., dextran coated charcoal. NCI CDE: 3131993"),
  additional_pharmaceutical_therapy STRING OPTIONS(description="The yes/no indicator related to the additional administration of various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level after the return of a disease after a period of remission or new disease."),
  additional_radiation_therapy STRING OPTIONS(description="Text yes/no/unknown indicator to signify additional therapeutic application of radiation therapy after return of disease. NCI CDE: 3008761"),
  lymphovascular_invasion_present STRING OPTIONS(description="Lymphovascular invasion present"),
  pos_lymph_node_location_other STRING OPTIONS(description="Free-text field to capture another name of the location of the pathologically positive lymph node that is not already specified or mentioned. NCI CDE: 3151522"),
  pos_lymph_node_location STRING OPTIONS(description="Text term to represent the name of the location of the pathologically positive lymph node. NCI CDE: 3151519"),
  location_in_lung_parenchyma STRING OPTIONS(description="Location in lung parenchyma"),
  pulmonary_function_test_performed STRING OPTIONS(description="Yes/no indicator of wether pulmonary function test was performed"),
  pre_bronchodilator_fev1_fvc_percent STRING OPTIONS(description="Percentage value to represent result of Forced Expiratory Volume in 1 second (FEV1) divided by the Forced Vital Capacity (FVC) pre-bronchodilator. NCI CDE: 3302955"),
  kras_mutation_result STRING OPTIONS(description="Text term to signify the ability to detect a mutation on the KRAS non wild-type gene. NCI CDE: 3135074"),
  post_bronchodilator_fev1_percent STRING OPTIONS(description="Percentage value to represent result of Forced Expiratory Volume in 1 second (FEV1) divided by the Forced Vital Capacity (FVC) post-bronchodilator. NCI CDE: 3302956"),
  pre_bronchodilator_fev1_percent STRING OPTIONS(description="Percentage value to represent result of Forced Expiratory Volume in 1 second (FEV1) divided by the Forced Vital Capacity (FVC) pre-bronchodilator. NCI CDE: 3302955"),
  dlco_predictive_percent STRING OPTIONS(description="The result measuring the amount of carbon monoxide detected in a patient's lungs._A lab value of the percentage of predicted normal. NCI CDE: 6002276"),
  egfr_mutation_performed STRING OPTIONS(description="Indicator of whether or not an analysis for mutation in the EGFR gene was performed. NCI CDE: 6063955"),
  diagnosis STRING OPTIONS(description="Text name for the histologic subtype used to refine a diagnosis of lung cancer."),
  eml4_alk_translocation_result STRING OPTIONS(description="Text term that represents the specific exon identified with the EML4-ALK chromosomal translocation. NCI CDE: 6063968"),
  egfr_mutation_result STRING OPTIONS(description="Text term to signify the ability to detect a mutation on the EGFR gene. NCI CDE: 3774251"),
  post_bronchodilator_fev1_fvc_percent STRING OPTIONS(description="Percentage value to represent result of Forced Expiratory Volume in 1 second (FEV1) divided by the Forced Vital Capacity (FVC) post-bronchodilator. NCI CDE: 3302956"),
  eml4_alk_translocation_performed STRING OPTIONS(description="Indicator of whether or not an analysis for translocation in the EML4-ALK gene was performed. NCI CDE: 6063976"),
  eml4_alk_translocation_method STRING OPTIONS(description="eml4 alk translocation method"),
  days_to_new_tumor_event_after_initial_treatment STRING OPTIONS(description="The numeric value to represent the day of a new tumor event after initial treatment, regardless of the type of event. NCI CDE: 3104042"),
  hemoglobin_result STRING OPTIONS(description="Text term to represent the summary result of the medical procedure that involves testing a sample of blood for hemoglobin, red respiratory protein of erythrocytes, to help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time. NCI CDE: 3113466"),
  serum_calcium_result STRING OPTIONS(description="Text term to represent the summary result of the medical procedure that involves testing a sample of blood for serum calcium, the amount of calcium found in clear liquid part of the blood that remains after blood cells and clotting proteins have been removed. NCI CDE: 3113470"),
  platelet_qualitative_result STRING OPTIONS(description="The qualitative result of a laboratory test that involved testing a sample of blood for the level of platelets (plt). NCI CDE: 3104944"),
  number_of_lymphnodes_positive STRING OPTIONS(description="The number of lymph nodes involved with disease as determined by pathologic examination."),
  erythrocyte_sedimentation_rate_result STRING OPTIONS(description="The qualitative result of a laboratory test that involved testing a sample of blood for the level of erythrocyte sedimentation rate (esr, sedrate). NCI CDE: 3104952"),
  white_cell_count_result STRING OPTIONS(description="The value, in cells/mcl, for the medical procedure that involves testing a sample cerebrospinal fluid, the fluid flowing around the brain and spinal cord, for blood cells that are devoid of hemoglobin, capable of Ameboid motion and phagocytosis, and act as the principal components of the immune system."),
  malignant_neoplasm_metastatic_involvement_site STRING OPTIONS(description="Free text field to specify the anatomic location where evidence is detected for spread of cancer from a tumor composed of atypical neoplastic cells to another part of the body that is not already specified or mentioned. NCI CDE: 3178387"),
  other_metastatic_involvement_anatomic_site STRING OPTIONS(description="Text description of anatomic sites of metastatic carcinoma that are different from the ones previously identified."),
  birth_control_pill_history_usage_category STRING OPTIONS(description="Classification to represent a women's use of oral contraceptives/birth control pills. NCI CDE: 3104217"),
  alcohol_history_documented STRING OPTIONS(description="Indicator to signify whether or not the history of alcohol consumption was documented. NCI CDE: 3440205"),
  frequency_of_alcohol_consumption STRING OPTIONS(description="Indicating the frequency of alcohol consumed when the participant was actively drinking. NCI CDE: 2202064"),
  source_of_patient_death_reason STRING OPTIONS(description="Source of patient death reason"),
  days_to_diagnostic_mri_performed STRING OPTIONS(description="Numeric value that represents the day that a diagnostic magnetic resonance imaging scan was performed."),
  days_to_diagnostic_computed_tomography_performed STRING OPTIONS(description="Time interval from the date of Computed Tomography (CT) scan to the date of initial pathologic diagnosis, represented as a calculated number of days."),
  amount_of_alcohol_consumption_per_day STRING OPTIONS(description="Numeric value that represents on the days when a person drank, on average, about how many drinks they had."),
  family_history_of_cancer STRING OPTIONS(description="Text indicator to represent a report or record of a cancer diagnosis in any relative with whom one half of an individual\"s genes is shared (i.e., parent, sibling, offspring). NCI CDE: 2436860"),
  loss_expression_of_mismatch_repair_proteins_by_ihc_result STRING OPTIONS(description="Loss expression of mismatch repair proteins by ihc result"),
  preoperative_pretreatment_cea_level STRING OPTIONS(description="Preoperative pretreatment cea level"),
  microsatellite_instability STRING OPTIONS(description="The yes/no indicator to signify the status of a tumor for microsatellite instability. NCI CDE: 6032776"),
  number_of_loci_tested STRING OPTIONS(description="Text number of the amount of loci found to be abnormal tested to detect recessive mutations"),
  history_of_colon_polyps STRING OPTIONS(description="History of colon polyps"),
  number_of_first_degree_relatives_with_cancer_diagnosis STRING OPTIONS(description="Numeric value that represents the number of first degree relatives (parent, sibling, and/or child) diagnosed with cancer."),
  number_of_abnormal_loci STRING OPTIONS(description="Text number of the amount of loci found to be abnormal tested to detect recessive mutations"),
  circumferential_resection_margin STRING OPTIONS(description="Numeric value used to describe the non-peritonealised bare area of rectum, comprising anterior and posterior segments, when submitted as a surgical specimen resulting from excision of cancer of the rectum. NCI CDE: 6161030"),
  non_nodal_tumor_deposits STRING OPTIONS(description="Text indicator to describe the identification of the presence of tumor deposits in the pericolic or perirectal fat or in adjacent mesentery away from the leading edge of the tumor. NCI CDE: 3107051"),
  braf_gene_analysis_result STRING OPTIONS(description="Text term to identify the result of the Mutational analysis and sequencing of the BRAF gene. NCI CDE: 3107189"),
  colon_polyps_present STRING OPTIONS(description="Text to identify the name of a city in which the sample was procured."),
  kras_mutation_codon STRING OPTIONS(description="KRAS Gene Mutation Other Position"),
  braf_gene_analysis_performed STRING OPTIONS(description="Indicator of whether or not an analysis for mutation in the BRAF gene was performed. NCI CDE: 6061813"),
  synchronous_colon_cancer_present STRING OPTIONS(description="The yes/no indicator whether synchronous colon cancer is present. NCI CDE: 2185953"),
  loss_expression_of_mismatch_repair_proteins_by_ihc STRING OPTIONS(description="Loss expression of mismatch repair proteins by ihc"),
  barretts_esophagus STRING OPTIONS(description="Barretts esophagus"),
  city_of_procurement STRING OPTIONS(description="Text to identify the name of a city in which the sample was procured."),
  reflux_history STRING OPTIONS(description="The yes/no/unknown/not reported indicator used to describe patients/participants who have a history of reflux disease. NCI CDE: 6059631"),
  country_of_procurement STRING OPTIONS(description="Text term that describes the name of the country where the specimen was collected."),
  antireflux_treatment_type STRING OPTIONS(description="A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa. An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process. The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes. A specific point in the time continuum, including those established relative to an event. Given. Type; a subdivision of a particular kind of thing."),
  h_pylori_infection STRING OPTIONS(description="The yes/no/unknown indicator that identifies patients/participants who have a previous or current diagnosis of H. pylori infection. NCI CDE: 3203146"),
  hypertension STRING OPTIONS(description="A human being._Abnormally high blood pressure._Indicator of Yes or No to a question. NCI CDE: 2935342"),
  horm_ther STRING OPTIONS(description="Text description of the current status of a woman's use of hormone replacement therapy after menopause. NCI CDE: 3012813"),
  pln_pos_ihc STRING OPTIONS(description="Number of peripheral lymph nodes by immunohistochemistry"),
  surgical_approach STRING OPTIONS(description="Text description, or term used, for the type of surgical procedure that was performed on a patient. NCI CDE: 5653325"),
  pregnancies STRING OPTIONS(description="The number of times, including this event, where a female participant conceived and became pregnant regardless of outcome."),
  diabetes STRING OPTIONS(description="The indicator that describes the absence or presence of whether or not diabetes, a disease in which the body does produce enough insulin or does not use properly and is unable to control the amount of sugar in the blood, that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person is present during the indicated period. NCI CDE: 3610965"),
  peritoneal_wash STRING OPTIONS(description="An indication of whether peritoneal washings were collected. NCI CDE: 5664775"),
  pct_tumor_invasion STRING OPTIONS(description="Value for percent calculated as depth of myometrial invasion divided by depth of myometrial thickness."),
  prior_tamoxifen_administered_usage_category STRING OPTIONS(description="Information related to past tamoxifen administered._Earlier in time or order._An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04)_A manner, or usual, or accepted practice of using something._Category; used informally to mean a class of things. NCI CDE: 3104234"),
  colorectal_cancer STRING OPTIONS(description="The yes/no indicator that identifies subjects with a current cancer diagnosis of pancreatic, colorectal or lung cancer. NCI CDE: 3528541"),
  total_aor_lnp STRING OPTIONS(description="Total aor lnp"),
  pln_pos_light_micro STRING OPTIONS(description="Pln pos light micro"),
  total_pelv_lnp STRING OPTIONS(description="Total pelv lnp"),
  total_pelv_lnr STRING OPTIONS(description="Total pelv lnr"),
  aln_pos_light_micro STRING OPTIONS(description="The number of positive axillary lymph nodes by ligth-microscopy."),
  aln_pos_ihc STRING OPTIONS(description="The number of positive axillary lymph nodes by immunohistochemistry (IHC)."),
  total_aor_lnr STRING OPTIONS(description="Total aor lnr"),
  post_surgical_procedure_assessment_thyroid_gland_carcinoma_status STRING OPTIONS(description="Text term to describe a person's condition within three months after surgery and adjuvant therapy to treat a thyroid gland carcinoma. NCI CDE: 3186684"),
  metastatic_neoplasm_confirmed_diagnosis_method_text STRING OPTIONS(description="Free text field to specify the name of the method used to establish or verify identification of a tumor that has spread from its original (primary) site of growth to another site that is not already specified or mentioned. NCI CDE: 3178376"),
  metastatic_neoplasm_confirmed_diagnosis_method_name STRING OPTIONS(description="Text term to represent the name of the method used to establish or verify identification of a tumor that has spread from its original (primary) site of growth to another site. NCI CDE: 3178364"),
  prior_glioma STRING OPTIONS(description="Yes/no indicator to history of prior glioma (GBM)"),
  tumor_residual_disease STRING OPTIONS(description="Residual disease (RD) status, 1-10 mm, >20 mm,11-20 mm"),
  jewish_origin STRING OPTIONS(description="Text names for Jewish heritage categories for a patient/participant on a clinical trial."),
  distant_metastasis_anatomic_site STRING OPTIONS(description="Distant Metastasis Location Anatomic Site"),
  new_neoplasm_event_type STRING OPTIONS(description="Text term to identify a new tumor event. NCI CDE: 3119721"),
  lymphnode_dissection_method_left STRING OPTIONS(description="Lymphnode dissection method left"),
  lymphnode_neck_dissection STRING OPTIONS(description="Lymphnode neck dissection"),
  egfr_amplication_status STRING OPTIONS(description="Text term to represent the status of the EGFR amplification."),
  hpv_status_by_ish_testing STRING OPTIONS(description="A procedure to determine the HPV status by ICH."),
  presence_of_pathological_nodal_extracapsular_spread STRING OPTIONS(description="Presence of pathological nodal extracapsular spread"),
  p53_gene_analysis STRING OPTIONS(description="Text term to describe the status of the p53 gene. NCI CDE: 3124938"),
  hpv_status_by_p16_testing STRING OPTIONS(description="HPV status by p16 testing"),
  lymphnode_dissection_method_right STRING OPTIONS(description="Lymphnode dissection method right"),
  eml4_alk_translocation_identified STRING OPTIONS(description="Indicator of whether or not a EML4-ALK chromosomal translocation was identified. NCI CDE: 6063959"),
  egfr_mutation_identified STRING OPTIONS(description="Indicator of whether or not a mutation abnormality in the EGFR gene was identified."),
  supratentorial_localization STRING OPTIONS(description="The named locations of a grade I or grade II glioma arising from the intracranial venous sinus that lies in a superior and midline location above the interhemispheric fissure along the superior border of the falx cerebri of the brain. NCI CDE: 7114355"),
  mold_or_dust_allergy_history STRING OPTIONS(description="Mold or dust allergy history"),
  motor_movement_changes STRING OPTIONS(description="Motor movement changes"),
  inherited_genetic_syndrome_found STRING OPTIONS(description="Inherited genetic syndrome found"),
  seizure_history STRING OPTIONS(description="The yes/no/unknown response related to the participant's medical history of epilepsy/seizure disorder. NCI CDE: 3194632"),
  asthma_history STRING OPTIONS(description="A yes or no indicator to ask whether there is a history of asthma. NCI CDE: 2178041"),
  first_diagnosis_age_asth_ecz_hay_fev_mold_dust STRING OPTIONS(description="First diagnosis age asth ecz hay fev mold dust"),
  first_diagnosis_age_of_food_allergy STRING OPTIONS(description="First diagnosis age of food allergy"),
  ldh1_mutation_found STRING OPTIONS(description="ldh1 mutation found"),
  tumor_location STRING OPTIONS(description="The site in or on the body at which the tumor identification test or result is performed or collected. NCI CDE: 6621372"),
  ldh1_mutation_test_method STRING OPTIONS(description="ldh1 mutation test method"),
  animal_insect_allergy_types STRING OPTIONS(description="Text name(s) of the specified type of allergy to animals or insects."),
  first_presenting_symptom STRING OPTIONS(description="The first symptom that is related to the metastatic disease of interest. NCI CDE: 7118710"),
  animal_insect_allergy_history STRING OPTIONS(description="A person's stated observation of whether or not they have animal or insect allergies"),
  first_presenting_symptom_longest_duration STRING OPTIONS(description="First presenting symptom longest duration"),
  ldh1_mutation_tested STRING OPTIONS(description="ldh1 mutation tested"),
  visual_changes STRING OPTIONS(description="Yes/no indicator of visual changes"),
  first_diagnosis_age_of_animal_insect_allergy STRING OPTIONS(description="first diagnosis age of animal insect allergy"),
  history_ionizing_rt_to_head STRING OPTIONS(description="History ionizing rt to head"),
  sensory_changes STRING OPTIONS(description="Sensory changes"),
  food_allergy_history STRING OPTIONS(description="A person's stated observation of whether or not they have any food allergies."),
  mental_status_changes STRING OPTIONS(description="Mental status changes"),
  hay_fever_history STRING OPTIONS(description="Yes/No/Unknown indicator to identify patients/ participants who have a personal history of hay fever (seasonal pollen allergies). NCI CDE: 3133930"),
  preoperative_corticosteroids STRING OPTIONS(description="Preoperative corticosteroids"),
  preoperative_antiseizure_meds STRING OPTIONS(description="Preoperative antiseizure meds"),
  family_history_of_primary_brain_tumor STRING OPTIONS(description="An indicator response which documents whether the parents, siblings or children of an individual have a history of a primary brain tumor. NCI CDE: 7118709"),
  inherited_genetic_syndrome_result STRING OPTIONS(description="Inherited genetic syndrome result"),
  days_to_initial_score_performance_status_scale STRING OPTIONS(description="Numeric value to represent the day of obtaining the initital score of the Performance Status Scale."),
  food_allergy_types STRING OPTIONS(description="Food allergy types"),
  headache_history STRING OPTIONS(description="Pain in various parts of the head, not confined to the area of distribution of any nerve. Subjective reports made by a patient. An account of all medical events and problems a person has experienced. A caDSR representation term that is used to indicate a question with permissible values of yes/no NCI CDE: 3109852"),
  eczema_history STRING OPTIONS(description="Yes/No/Unknown indicator to identify patients/ participants who have a personal history of eczema. NCI CDE: 3133925"),
  other_genotyping_outcome_lab_results_text STRING OPTIONS(description="Free text field to specify the results of other genotypic assessments of mutation that is not already specified or mentioned. NCI CDE: 3179278"),
  extrathyroid_carcinoma_present_extension_status STRING OPTIONS(description="Text term to describe the degree to which the primary tumor has extra thyroid extension. NCI CDE: 3179452"),
  i_131_first_administered_dose STRING OPTIONS(description="A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production._Preceding all others in time or space or degree._Given._The amount of medicine taken, or radiation given, at one time._Text; the words of something written. NCI CDE: 3232898"),
  i_131_subsequent_administered_dose STRING OPTIONS(description="A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production._Subsequent; immediately following in time or order._Given._The amount of medicine taken, or radiation given, at one time._Text; the words of something written. NCI CDE: 3232904"),
  i_131_total_administered_dose STRING OPTIONS(description="A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._Given._The amount of medicine taken, or radiation given, at one time._Text; the words of something written. NCI CDE: 3232906"),
  primary_neoplasm_focus_type STRING OPTIONS(description="Text term to describe whether the tumor or cancer first developed in a single or multiple locations. NCI CDE: 3174022"),
  i_131_total_administered_preparation_technique STRING OPTIONS(description="A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._Given._The act or process of making something ready; also a medication made ready for administration; also an anatomic or pathologic specimen made ready and preserved for study._A practiced and regimented skill or series of actions._The words or language units by which a thing is known. NCI CDE: 3232952"),
  person_lifetime_risk_radiation_exposure_indicator STRING OPTIONS(description="Text term to signify whether a person has been exposed to ionizing radiation. [Manually-curated] NCI CDE: 2816350"),
  ret_ptc_rearrangement_genotyping_outcome_lab_results_text STRING OPTIONS(description="Free text field to specify the results of genotypic assessment of mutation in the RET/PEC gene. NCI CDE: 3179271"),
  genotyping_results_gene_mutation_not_reported_reason STRING OPTIONS(description="Text term to capture the explanation related to missing results for genotypic analysis. NCI CDE: 3179383"),
  neoplasm_depth STRING OPTIONS(description="The measurement extent downward or inward of remaining tumor expressed using Breslow 's thickness: maximal thickness of a primary cutaneous melanoma measured in tissue sections from the top of the epidermal granular layer, or from the ulcer base (if the tumor is ulcerated), to the bottom of the tumor, with metastatic rates correlating closely with tumor thickness. NCI CDE: 2593061"),
  genotype_analysis_performed_indicator STRING OPTIONS(description="Text indicator to signify whether or not genotypic analysis was performed. NCI CDE: 3179001"),
  ras_family_gene_genotyping_outcome_lab_results_text STRING OPTIONS(description="Free text field to specify the results of genotypic assessment of mutation in the RAS gene. NCI CDE: 3179266"),
  neoplasm_length STRING OPTIONS(description="Annotation used to indicate the length of cancer tissue in a specimen, measured in mm. NCI CDE: 5542978"),
  neoplasm_width STRING OPTIONS(description="Measurement of the width of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues within a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. NCI CDE: 3441689"),
  radiosensitizing_agent_administered_indicator STRING OPTIONS(description="Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells._Given._Indicator of Yes, No, or Unknown to represent a condition. NCI CDE: 3232932"),
  braf_gene_genotyping_outcome_lab_results_text STRING OPTIONS(description="Free text field to specify the results of genotypic assessment of mutation in the BRAF gene. NCI CDE: 3179257"),
  lymph_node_preoperative_scan_indicator STRING OPTIONS(description="Text indicator to signify whether or not the medical imaging of the lymph nodes was performed prior to surgery. NCI CDE: 3178301"),
  radiation_therapy_administered_preparation_technique_text STRING OPTIONS(description="Information related to radiation therapy administered to a patient._The act or process of making something ready; also a medication made ready for administration; also an anatomic or pathologic specimen made ready and preserved for study._A practiced and regimented skill or series of actions._Text; the words of something written. NCI CDE: 3232960"),
  lymph_node_preoperative_assessment_diagnostic_imaging_type STRING OPTIONS(description="Text term to describe the type of lymph node medical imaging that was performed prior to surgery. NCI CDE: 3178310"),
  patient_personal_medical_history_thyroid_gland_disorder_name STRING OPTIONS(description="Text term to represent the name of the thyroid gland disorder, found in the record of a patient's medical background. NCI CDE: 3176743"),
  first_degree_relative_history_thyroid_gland_carcinoma_diagnosis_relationship_type STRING OPTIONS(description="Text term to describe the relationship to the participant of the first degree family member who has a history of thyroid cancer. NCI CDE: 3179002"),
  radiation_therapy_administered_dose_text STRING OPTIONS(description="Information related to radiation therapy administered to a patient._The amount of medicine taken, or radiation given, at one time._Text; the words of something written. NCI CDE: 3232933"),
  patient_personal_medical_history_thyroid_other_specify_text STRING OPTIONS(description="Free text field to specify the name of the thyroid gland disorder, found in the record of a patient's medical background that is not already specified or mentioned. NCI CDE: 3179397"),
  primary_thyroid_gland_neoplasm_location_anatomic_site STRING OPTIONS(description="Text term to describe the specific location within the thyroid where the tumor or cancer first developed. NCI CDE: 3186750"),
  lymphnodes_examined STRING OPTIONS(description="Lymphnodes examined"),
  zone_of_origin STRING OPTIONS(description="A component of an address that specifies a location by identification of an area where products are manufactured."),
  days_to_bone_scan_performed STRING OPTIONS(description="Numeric value to represent the day that a bone scan was performed."),
  diagnostic_mri_performed STRING OPTIONS(description="The yes/no indicator that asks whether an MRI scan was performed. NCI CDE: 3534862"),
  diagnostic_mri_result STRING OPTIONS(description="Text term to describe the result of a magnetic resonance imaging diagnostic procedure. NCI CDE: 3151441"),
  psa_value STRING OPTIONS(description="The determination of the PSA (prostate specific antigen) present in a sample. NCI CDE: 7063440"),
  days_to_first_biochemical_recurrence STRING OPTIONS(description="Numeric value to represent the day of the first biochemical recurrence."),
  secondary_pattern STRING OPTIONS(description=" Numeric value indicating the second-most frequent pattern or pathologic grade for a specimen or groups of specimens as interpreted by a pathologist using the Gleason Score scale. NCI CDE: 1284"),
  primary_pattern STRING OPTIONS(description="Numeric value indicating the most frequent pattern or pathologic grade for a specimen or groups of specimens as interpreted by a pathologist using the Gleason Score scale. NCI CDE: 1282"),
  diagnostic_ct_abd_pelvis_result STRING OPTIONS(description="Diagnostic ct abd pelvis result"),
  bone_scan_results STRING OPTIONS(description="Yes/or no indicator for Information related to the results availability for a nuclear imaging method used to evaluate pathological bone metabolism."),
  biochemical_recurrence STRING OPTIONS(description="Indicator to ask if the patient has been diagnosed with a recurrence using biochemical markers."),
  tumor_level STRING OPTIONS(description="Text term to describe the site (apex, middle, base) within the prostate zonal anatomy used to identify the location of the tumor. NCI CDE: 7063204"),
  gleason_score STRING OPTIONS(description="The Gleason score that provides a reproducible description of the glandular architecture of prostate tissue depending primarily on the microscopic patterns of cancerous glands and cell morphology. NCI CDE: 2433"),
  number_of_lymphnodes_examined STRING OPTIONS(description="The total number of lymph nodes removed and pathologically assessed for disease."),
  days_to_psa STRING OPTIONS(description="Numeric value to represent the day that the most recent PSA was performed."),
  tertiary_pattern STRING OPTIONS(description="An integer representing the third most predominant Gleason pattern or grade present in an invasive prostate carcinoma. A teritary pattern can only be assigned in a radical prostatectomy specimen, and is not required. NCI CDE: 2431622"),
  diagnostic_ct_abd_pelvis_performed STRING OPTIONS(description="Yes/no indicator related to evaluation based on a method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis of the abdomen and pelvis."),
  family_medical_history_relative_family_member_relationship_type STRING OPTIONS(description="Family medical history relative family member relationship type"),
  tumor_type STRING OPTIONS(description="Text term to represent the category for a neoplasm's histologic subtype. NCI CDE: 2831122"),
  primary_tumor_multiple_present_ind STRING OPTIONS(description="Yes/no indicator to ask if multiple primary tumors were identified. NCI CDE: 64186"),
  prior_systemic_therapy_type STRING OPTIONS(description="Text term to describe a systemic therapy modality. NCI CDE: 3119700"),
  melanoma_clark_level_value STRING OPTIONS(description="Definition of the Clark level or depth of involvement of a melanoma in the skin or a specimen. NCI CDE: 2593051"),
  melanoma_origin_skin_anatomic_site STRING OPTIONS(description="Text term for the skin site from which a primary melanoma originates. NCI CDE: 3108474"),
  malignant_neoplasm_mitotic_count_rate STRING OPTIONS(description="Rate measured for the number of mitoses identified under the microscope in malignant neoplasm. NCI CDE: 3186135"),
  breslow_depth_value STRING OPTIONS(description="Value representating Breslow's thickness of a cutaneous melanoma measured in tissue sections from the top of the epidermal granular layer, or from the ulcer base (if the tumor is ulcerated), to the bottom of the tumor; metastatic rates correlate closely with tumor thickness. (from On-line Medical Dictionary) NCI CDE: 2593055"),
  tumor_tissue_site_1 STRING OPTIONS(description="Tumor Tissue Site"),
  melanoma_ulceration_indicator STRING OPTIONS(description="Text indicator to signify whether a melanoma has ulceration present. NCI CDE: 3108478"),
  primary_neoplasm_melanoma_dx STRING OPTIONS(description="Primary neoplasm melanoma dx"),
  new_tumor_dx_prior_submitted_specimen_dx STRING OPTIONS(description="New tumor dx prior submitted specimen dx"),
  primary_anatomic_site_count STRING OPTIONS(description="Occurring first in time or sequence; original; of greatest rank or importance or value._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._Named locations of or within the body._Count of the number of tumors classified as primaries, not sites of metastatic disease. NCI CDE: 2967294"),
  interferon_90_day_prior_excision_admin_indicator STRING OPTIONS(description="The yes/no/unknown indicator to determine whether the patient received IFN therapy 90 days prior to the resection of the specimen submitted. NCI CDE: 3162803"),
  primary_melanoma_at_diagnosis_count STRING OPTIONS(description="Total number of the known primary tumors at the time of initial diagnosis. NCI CDE: 3427429"),
  days_to_submitted_specimen_dx STRING OPTIONS(description="Numeric value to represent the day of the diagnosis for the submitted sample."),
  antireflux_treatment STRING OPTIONS(description="The yes/no/unknown indicator that identifies patients/participants who were receiving anti-reflux treatment at the time of sample procurement."),
  number_of_relatives_with_stomach_cancer STRING OPTIONS(description="A numeric value to represent the number of first degree relatives (parents, siblings, children) who have been diagnosed with stomach cancer."),
  family_history_of_stomach_cancer STRING OPTIONS(description="An indicator response which documents if a family history of stomach cancer. NCI CDE: 7063047"),
  state_province_country_of_procurement STRING OPTIONS(description="State province country of procurement"),
  specimen_collection_method_name STRING OPTIONS(description="The type of procedure or method used to collect a biospecimen or tissue sample. NCI CDE: 3131309"),
  child_pugh_classification_grade STRING OPTIONS(description="The grade from an assessment method used in the prognosis of chronic liver disease, mainly cirrhosis. NCI CDE: 2931791"),
  hist_of_non_mibc STRING OPTIONS(description="Hist of non mibc"),
  occupation_primary_job STRING OPTIONS(description="The primary occupation of the participant for most of their adult employment. NCI CDE: 5714"),
  person_concomitant_prostate_carcinoma_occurrence_indicator STRING OPTIONS(description="Text term to signify a person's diagnosis of prostatic carcinoma incidentally or at the same time as another cancer diagnosis, such as bladder carcinoma. NCI CDE: 3135387"),
  person_concomitant_prostate_carcinoma_pathologic_t_stage STRING OPTIONS(description="Code to represent the extent of incidental or concomitant prostate carcinoma in the primary tumor site based on pathological assessment and the staging guidelines from the AJCC edition 7.0. NCI CDE: 3135398"),
  cancer_diagnosis_cancer_type_icd9_text_name STRING OPTIONS(description="Diagnosis represented as a character short name using ICD-9 cancer types. NCI CDE: 2195089"),
  non_mibc_tx STRING OPTIONS(description="Non mibc tx"),
  bladder_carcinoma_extracapsular_extension_status STRING OPTIONS(description="Text term to describe the extent of extracapsular extension present in a case of bladder carcinoma. NCI CDE: 3130374"),
  chemical_exposure_text STRING OPTIONS(description="A free text field to specify an exposure to a substance with a defined atomic or molecular structure that results from, or takes part in, reactions involving changes in its structure, composition, or properties. NCI CDE: 2596673"),
  resp_maint_from_bcg_admin_month_dur STRING OPTIONS(description="Resp maint from bcg admin month dur"),
  maint_therapy_course_complete STRING OPTIONS(description="Indicator to signify whether or not the patient completed one or more courses of maintenance therapy. NCI CDE: 3436266"),
  induction_course_complete STRING OPTIONS(description="Indicator to signify whether or not the patient completed one or more courses of neoadjvant therapy. NCI CDE: 3436265"),
  person_occupation_years_number STRING OPTIONS(description="The number that describes the duration of time expressed in number of years that a person has worked in a job. NCI CDE: 2435424"),
  person_primary_industry_text STRING OPTIONS(description="Text to describe the industry in which a person's primary occupation time was spent. NCI CDE: 3135408"),
  disease_extracapsular_extension_ind_3 STRING OPTIONS(description=" Yes/no/unknown indicator that asks whether or not there is extracapsular extension. NCI CDE: 64165"),
  complete_response_observed STRING OPTIONS(description="Indicator to signify whether or not the patient had a complete response to treatment. NCI CDE: 3436262"),
  diagnosis_subtype STRING OPTIONS(description="Pathologic Subtype"),
  diagnosis_age STRING OPTIONS(description="The numerical response indicating the age of a person, expressed in years, when they were diagnosed with a disease or disorder. NCI CDE: 4828691"),
  mibc_90day_post_resection_bcg STRING OPTIONS(description="Mibc 90day post resection bcg"),
  person_occupation_description_text STRING OPTIONS(description="The text that describes the type of business or industry associated with a person's job. NCI CDE: 2435398"),
  surgical_procedure_name_other_specify_text STRING OPTIONS(description="The free-text field used to describe the name assigned to a surgical procedure done for diagnostic, surveillance, treatment, palliation, or study-directed purposes. NCI CDE: 3121814"),
  relative_family_cancer_history_ind_3 STRING OPTIONS(description="Yes/no/unknown indicator that asks whether any blood relatives have ever been diagnosed with cancer. NCI CDE: 2691192"),
  vascular_tumor_cell_invasion_type STRING OPTIONS(description="Text term that represents the type of vascular tumor invasion. NCI CDE: 3168001"),
  viral_hepatitis_serology STRING OPTIONS(description="Text term that describes the kind of serological laboratory test used to determine the positive or negative test result for hepatitis. NCI CDE: 4395982"),
  liver_fibrosis_ishak_score_category STRING OPTIONS(description="The score or group of scores as described by Dr. Kamal G. Ishak and colleagues to assess the histopathologic degree of liver damage. NCI CDE: 3182621"),
  ablation_embolization_tx_adjuvant STRING OPTIONS(description="Text indicator to signify whether or not the adjuvant ablation or embolization was performed post-operatively. Yes No Unknown Indicator. NCI CDE: 3172120"),
  laboratory_procedure_prothrombin_time_result_value STRING OPTIONS(description="Numeric laboratory value of the prothrombin coagulation time in peripheral blood. NCI CDE: 2459694"),
  laboratory_procedure_creatinine_result_lower_limit_of_normal_value STRING OPTIONS(description="Lower limit of normal of a renal creatinine lab. NCI CDE: 2234697"),
  laboratory_procedure_alpha_fetoprotein_outcome_value STRING OPTIONS(description="The numerical quantity measured for laboratory result for alpha fetoprotein. NCI CDE: 2932074"),
  laboratory_procedure_alpha_fetoprotein_outcome_upper_limit_of_normal_value STRING OPTIONS(description="A numerical quantity measured that is the top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter for alpha fetoprotein (a protein normally produced by a developing fetus). NCI CDE: 2932064"),
  laboratory_procedure_alpha_fetoprotein_outcome_lower_limit_of_normal_value STRING OPTIONS(description="A numerical quantity measured that is the bottom value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter for alpha fetoprotein (a protein normally produced by a developing fetus). NCI CDE: 3171861"),
  laboratory_procedure_albumin_result_upper_limit_of_normal_value STRING OPTIONS(description="Laboratory procedure albumin result upper limit of normal value"),
  laboratory_procedure_albumin_result_specified_value STRING OPTIONS(description="The value of a lab test used to determine the albumin level in the blood. NCI CDE: 58274"),
  laboratory_procedure_creatinine_result_upper_limit_of_normal_value STRING OPTIONS(description="The value, in mg/dL, for the upper limit of normal for the medical procedure that involves testing a sample of blood for creatinine, the breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function. NCI CDE: 2183392"),
  laboratory_prcoedure_platelet_result_upper_limit_of_normal_value STRING OPTIONS(description="Laboratory prcoedure platelet result upper limit of normal value"),
  lab_procedure_platelet_result_specified_value STRING OPTIONS(description="The absolute peripheral platelet count (in 1000/mcL). NCI CDE: 58304"),
  days_to_definitive_surgical_procedure_performed STRING OPTIONS(description="Numeric value that represents the day definitive surgical procedure was performed."),
  hematology_serum_creatinine_laboratory_result_value_in_mg_dl STRING OPTIONS(description="A value which captures the amount of Creatinine in the blood measured in milligrams per deciliter (mg/dL). Creatinine is derived from a constituent of muscle tissue, which is used to evaluate kidney glomerular filtration. [Manually-curated] NCI CDE: 2655822"),
  history_hepato_carcinoma_risk_factor STRING OPTIONS(description="An individual's attribute, characteristic or exposure that increases the likelihood of developing a disease (WHO) that arises from hepatocytes resulting in hepatocellular carcinoma, or as diffuse liver involvement. NCI CDE: 7118713"),
  history_hepato_carcinoma_risk_factor_other STRING OPTIONS(description="History hepato carcinoma risk factor other"),
  cancer_diagnosis_first_degree_relative_number STRING OPTIONS(description="Numeric value that represents the number of first degree relatives (parent, sibling, and/or child) diagnosed with cancer. NCI CDE: 3171640"),
  laboratory_prcoedure_platelet_result_lower_limit_of_normal_value STRING OPTIONS(description="Laboratory prcoedure platelet result lower limit of normal value"),
  laboratory_procedure_international_normalization_ratio_result_lower_limit_of_normal_value STRING OPTIONS(description="Lower limit of normal of the International Normalization Ratio value. NCI CDE: 2799755"),
  laboratory_procedure_albumin_result_lower_limit_of_normal_value STRING OPTIONS(description="The numeric laboratory value representing the lower level of the normal range of values for Albumin in peripheral blood serum used to comparatively reference the patient's lab result NCI CDE: 2004085"),
  laboratory_procedure_total_bilirubin_result_specified_lower_limit_of_normal_value STRING OPTIONS(description="Laboratory procedure total bilirubin result specified lower limit of normal value"),
  laboratory_procedure_total_bilirubin_result_specified_upper_limit_of_normal_value STRING OPTIONS(description="The institutional upper limit of normal value in mg/dL for the procedure that involves testing or manipulating a sample of blood in a laboratory setting for total bilirubin, a breakdown product of hemoglobin, liver lab. NCI CDE: 2003891"),
  laboratory_procedure_total_bilirubin_result_upper_limit_normal_value STRING OPTIONS(description="The numeric laboratory value (units not specified) for the procedure that involves testing or manipulating a sample of blood in a laboratory setting for total bilirubin, a breakdown product of hemoglobin, liver lab. NCI CDE: 2004060"),
  adjacent_hepatic_tissue_inflammation_extent_type STRING OPTIONS(description="Text term that represents the extent of active hepatic inflammation in adjacent tissue. NCI CDE: 3173974"),
  laboratory_procedure_international_normalization_ratio_result_upper_limit_of_normal_value STRING OPTIONS(description="The upper limit of normal of the International Normalization Ratio value. NCI CDE: 2190394"),
  mitotic_count STRING OPTIONS(description="Numeric response that indicates the mitoses counted microscopically per high power field. NCI CDE: 7069579"),
  oligonucleotide_primer_pair_laboratory_procedure_performed_name STRING OPTIONS(description="Text term to represent the name of the method of oligonucleotide primer pair testing. NCI CDE: 3151487"),
  radiation_type_notes STRING OPTIONS(description="Radiation type notes"),
  number_of_successful_pregnancies_which_resulted_in_at_least_1_live_birth STRING OPTIONS(description="Count of the number of successful pregnancies that resulted in the birth of at least one child."),
  external_beam_radiation_therapy_administered_paraaortic_region_lymph_node_dose STRING OPTIONS(description="Numeric value to represent the total dose in cGY of external beam radiation treatment administered to the paraaortic nodes. NCI CDE: 3151106"),
  concurrent_chemotherapy_dose STRING OPTIONS(description="Occurring or operating at the same time._The use of synthetic or naturally-occurring chemicals for the treatment of diseases. Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer. Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells. Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents. Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_The total quantity or strength of a substance (drug or radiation) administered at one time. (NCI) NCI CDE: 3166172"),
  chemotherapy_regimen_type STRING OPTIONS(description="The chemotherapy regimen or schedule and agent in the therapy of patient NCI CDE: 2007212"),
  chemotherapy_negation_radiation_therapy_concurrent_not_administered_reason STRING OPTIONS(description="Text term to capture the explanation for a chemotherapy not being given concurrent to radiation therapy. NCI CDE: 3151120"),
  postoperative_rx_tx_1 STRING OPTIONS(description="Yes/no indicator of postoperative radiology treatment"),
  dose_frequency_text STRING OPTIONS(description="The text that represents the planned dosage frequency for a agent. NCI CDE: 2179580"),
  rt_pelvis_administered_total_dose STRING OPTIONS(description="A numeric value for the total dose volume of radiation therapy given to critical anatomic structures in the pelvic region. NCI CDE: 3006"),
  cervical_neoplasm_pathologic_margin_involved_type STRING OPTIONS(description="Text term to describe the type of cervical cancer margin involvement. NCI CDE: 3151541"),
  cervical_neoplasm_pathologic_margin_involved_text STRING OPTIONS(description="Free-text field to capture another type of cervical cancer margin involvement that is not already specified or mentioned. NCI CDE: 3151544"),
  cervical_carcinoma_pelvic_extension_text STRING OPTIONS(description="Text term to capture comments related to the cervical cancer pelvic extension. NCI CDE: 3151605"),
  cervical_carcinoma_corpus_uteri_involvement_indicator STRING OPTIONS(description="Text indicator to signify whether or not there was corpus uteri involvement. NCI CDE: 3151610"),
  ectopic_pregnancy_count STRING OPTIONS(description="Number of ectopic pregnancies in a woman's history. NCI CDE: 2261915"),
  rt_administered_type STRING OPTIONS(description="The type of radiation therapy given to a patient. NCI CDE: 61468"),
  oligonucleotide_primer_pair_laboratory_procedure_performed_text STRING OPTIONS(description="Free-text field to capture another name for the method of oligonucleotide primer pair testing that is not already specified or mentioned. NCI CDE: 3151490"),
  other_chemotherapy_agent_administration_specify STRING OPTIONS(description="Free-text field to specify the other chemotherapy agent administered. NCI CDE: 2426129"),
  radiation_therapy_not_administered_reason STRING OPTIONS(description="The reason radiation therapy was not administered or given. NCI CDE: 2733266"),
  patient_pregnancy_therapeutic_abortion_count STRING OPTIONS(description="The number of times for which a female participant conceived and became pregnant, but did not carry fetus to term due to medical intervention to end the pregnancy. NCI CDE: 2180648"),
  days_to_laboratory_procedure_tumor_marker_squamous_cell_carcinoma_antigen_result STRING OPTIONS(description="Time interval from the date of Squamous Cellular Carcinoma Antigen (SCCA) Tumor Marker Result to the date of initial pathologic diagnosis, represented as a calculated number of days. NCI CDE: 5654374"),
  days_to_performance_status_assessment STRING OPTIONS(description="The date of the final result of a determination of the value, significance, or extent of how well a patient is able to perform ordinary tasks and carry out daily activities."),
  prescribed_dose_units STRING OPTIONS(description="Code to represent the unit of measure (UOM) associated with a prescribed dose for treatment. NCI CDE: 3065815"),
  diagnostic_ct_result_outcome STRING OPTIONS(description="Text term to describe the result of a computed tomography diagnostic procedure. NCI CDE: 3151439"),
  patient_pregnancy_spontaneous_abortion_count STRING OPTIONS(description="the number of times for which a female participant conceived and became pregnant, but did not carry fetus to term due to natural occurrences or problems during the pregnancy. NCI CDE: 2180637"),
  patient_pregnancy_count STRING OPTIONS(description="The number of times, including this event, where a female participant conceived and became pregnant regardless of outcome. NCI CDE: 2180638"),
  fdg_or_ct_pet_performed_outcome STRING OPTIONS(description="Text term to describe the result of a fludeoxyglucose F 18 or computed tomography positron emission tomography scan. NCI CDE: 3151497"),
  female_breast_feeding_or_pregnancy_status_indicator STRING OPTIONS(description="Text term to signify whether a woman is pregnant or nursing. NCI CDE: 3012573"),
  standardized_uptake_value_cervix_uteri_assessment_measurement STRING OPTIONS(description="Numeric value that represents the standardized uptake of a positron emission tomography assessment measurement. NCI CDE: 3151615"),
  pregnant_at_diagnosis STRING OPTIONS(description="A yes/no indicator that asks whether the patient was pregnant at diagnosis."),
  pregnancy_stillbirth_count STRING OPTIONS(description="Incidence of stillbirth as part of a woman's pregnancy history. NCI CDE: 2183304"),
  patient_history_immune_system_and_related_disorders_text STRING OPTIONS(description="Free-text field to capture another name of immunosuppressive disease in the medical history of a patient that is not already specified or mentioned. NCI CDE: 3151449"),
  patient_history_immune_system_and_related_disorders_name STRING OPTIONS(description="Text term to represent the name of immunosuppressive disease in the medical history of a patient. NCI CDE: 3151446"),
  days_to_fdg_or_ct_pet_performed STRING OPTIONS(description="Time interval from the date of FDG-Positron Emission Tomography to the date of initial pathologic diagnosis, represented as a calculated number of days."),
  diagnostic_mri_result_outcome STRING OPTIONS(description="Text term to describe the result of a magnetic resonance imaging diagnostic procedure. NCI CDE: 3151441"),
  radiation_therapy_1 STRING OPTIONS(description="The yes/no indicator related to the administration of target radiation therapy NCI CDE: 3257225"),
  radiation_therapy_not_administered_specify STRING OPTIONS(description="The free-text field to specify the reason radiation therapy was not administered or given. NCI CDE: 2733267"),
  human_papillomavirus_laboratory_procedure_performed_name STRING OPTIONS(description="Text term to represent the name of the method of human papillomavirus testing. NCI CDE: 3151457"),
  chemotherapy_negation_radiation_therapy_concurrent_administered_text STRING OPTIONS(description="Free-text field to capture another reason that is not already specified or mentioned for why concurrent chemotherapy was not given. NCI CDE: 3151824"),
  lymph_node_location_positive_pathology_name STRING OPTIONS(description="Text term to represent the name of the location of the pathologically positive lymph node. NCI CDE: 3151519"),
  keratinizing_squamous_cell_carcinoma_present_indicator STRING OPTIONS(description="Term relates to cell type describing degree of squamous differentiation. Keratinizing tumors have at least one well formed keratin pearl. All other patters are non-keratinizing. NCI CDE: 3151599"),
  laboratory_procedure_tumor_marker_squamous_cell_carcinoma_antigen_result_value STRING OPTIONS(description="Numeric value to represent tumor marker Squamous Cell Carcinoma Antigen result. NCI CDE: 3151234"),
  total_number_of_pregnancies STRING OPTIONS(description="Total number of pregnancies"),
  hysterectomy_Performed_Ind_3 STRING OPTIONS(description="The yes/no/unknown indicator that asks whether the patient had a hysterectomy. NCI CDE: 2001892"),
  hysterectomy_performed_text STRING OPTIONS(description="Free-text field to capture another type of hysterectomy procedure performed that is not already specified or mentioned. NCI CDE: 3151506"),
  human_papillomavirus_other_type_text STRING OPTIONS(description="Any of various papillomaviruses that infect the skin and mucous membranes of humans.sometimes progress to malignancy._Different than the one(s) previously specified or mentioned._Something distinguishable as an identifiable class based on common qualities._Text; the words of something written. NCI CDE: 3166168"),
  hysterectomy_performed_type STRING OPTIONS(description="The type of hysterectomy being performed. NCI CDE: 2647164"),
  lymphovascular_invasion_indicator STRING OPTIONS(description="Of or relating to the lymphatic vessels.:Local spread of a malignant neoplasm by infiltration or destruction of adjacent tissue; for epithelial neoplasms, invasion signifies infiltration beneath the epithelial basement membrane._Records whether dermal lymphatics invasion was present in the specimen under consideration. NCI CDE: 5543272"),
  brachytherapy_first_reference_point_administered_total_dose STRING OPTIONS(description="Numeric value to represent the total dose in cGY of brachytherapy treatment given to the first reference point. NCI CDE: 3151100"),
  brachytherapy_method_other_specify_text STRING OPTIONS(description="Free-text field to capture another type of brachytherapy treatment given that is not already specified or mentioned. NCI CDE: 3150976"),
  lymph_node_location_positive_pathology_text STRING OPTIONS(description="Free-text field to capture another name of the location of the pathologically positive lymph node that is not already specified or mentioned. NCI CDE: 3151522"),
  tumor_response_cdus_type STRING OPTIONS(description="The evaluation of tumor response by comparing the baseline tumor measurements to those taken after protocol intervention, per CDUS reporting requirements. NCI CDE: 2178525"),
  brachytherapy_method_type STRING OPTIONS(description="The type of brachytherapy method used. NCI CDE: 2966127"),
  agent_total_dose_count STRING OPTIONS(description="A total number of doses of a drug, vaccine or other agent administered to a patient. NCI CDE: 2180805"),
  live_birth_number STRING OPTIONS(description="The number of live births the participant has experienced. NCI CDE: 2486644"),
  human_papillomavirus_laboratory_procedure_performed_text STRING OPTIONS(description="Free-text field to capture another name for the method of human papillomavirus testing that is not already specified or mentioned. NCI CDE: 3151460"),
  human_papillomavirus_type STRING OPTIONS(description="Text classification to represent the strain or type of human papillomavirus identified in an individual. NCI CDE: 2922649"),
  performance_status_assessment_timepoint_category_other_text STRING OPTIONS(description="Text description of an 'other' performance status timing scale used in conjunction with a patient's therapy. NCI CDE: 3151756"),
  ct_scan STRING OPTIONS(description="A Yes/No reponse to signify that a lesion or disease was seen on Computer Tomography (CT) scan. NCI CDE: 2004007"),
  new_neoplasm_event_occurrence_anatomic_site STRING OPTIONS(description="New neoplasm event occurrence anatomic site"),
  radiologic_tumor_width STRING OPTIONS(description="Numeric value for the width of the tumor reported on the computed tomography or magnetic resonance imaging immediately preceding the surgical resection. NCI CDE: 3528033"),
  contiguous_organ_resection_site STRING OPTIONS(description="Text term to represent the name of the organ resected that was contiguous to the primary disease site."),
  radiologic_tumor_depth STRING OPTIONS(description="Numeric value for the depth of the tumor reported on the computed tomography or magnetic resonance imaging immediately preceding the surgical resection. NCI CDE: 3528032"),
  radiologic_tumor_burden STRING OPTIONS(description="Numeric value of the sum of the maximum diameter of the primary tumor as reported on the computed tomography or magnetic resonance imaging at the time of the surgical resection. NCI CDE: 3532297"),
  tumor_depth STRING OPTIONS(description="Text term for the degree to which a tumor has penetrated into organ or tissue. NCI CDE: 3808610"),
  pathologic_tumor_width STRING OPTIONS(description="Numeric value for the width of the tumor as examined pathologically at the time of the surgical resection. NCI CDE: 3528041"),
  tumor_multifocal STRING OPTIONS(description="Yes/no indicator to ask if the tumor is multifocal. NCI CDE: 64356"),
  other_contiguous_organ_resection_site STRING OPTIONS(description="Touching or very close together. A part of the body that performs a specific function. For example, the heart is an organ. Removal or excision by surgical measures. Performed; carried out. A free text field used to describe a location of a position, site, or point in space where something can be found."),
  contiguous_organ_invaded STRING OPTIONS(description="Text indicator to signify whether or not the disease penetrated from the primary site to a contiguous site. NCI CDE: 3162817"),
  pathologic_tumor_length STRING OPTIONS(description="Numeric value for the length of the tumor as examined pathologically at the time of the surgical resection. NCI CDE: 3528034"),
  pathologic_tumor_depth STRING OPTIONS(description="Numeric value for the depth of the tumor as examined pathologically at the time of the surgical resection. NCI CDE: 3528040"),
  pathologic_tumor_burden STRING OPTIONS(description="Numeric value of the sum of the maximum diameter of the new tumor as examined pathologically at the time of the surgical resection. NCI CDE: 3532298"),
  radiologic_tumor_length STRING OPTIONS(description="Numeric value for the length of the tumor reported on the computed tomography or magnetic resonance imaging immediately preceding the surgical resection. NCI CDE: 3528021"),
  tumor_total_necrosis_percent STRING OPTIONS(description="Text that represents the total amount of necrosis found in a sarcoma tumor. NCI CDE: 3300612"),
  primary_tumor_lower_uterus_segment STRING OPTIONS(description="The original tumor._Lower; the bottom one of two._The hollow muscular organ in which the impregnated ovum is developed into the child; it is about 7.5 cm in length in the nonpregnant woman, and consists of a main portion (body) with an elongated lower part (neck), at the extremity of which is the opening (os). The upper rounded portion of the uterus, opposite the os, is the fundus, at each extremity of which is the horn marking the part where the uterine tube joins the uterus and through which the ovum reaches the uterine cavity after leaving the ovary. The organ is supported in the pelvic cavity by the broad ligaments, round ligaments, cardinal ligaments, and rectouterine and vesicouterine folds or ligaments. SYN metra, womb._One of the parts into which something naturally divides._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied. NCI CDE: 2775554"),
  days_to_well_differentiated_liposarcoma_resection STRING OPTIONS(description="Numeric value that represents the day that a resection of a well differentiated liposarcoma was performed."),
  metastatic_site_at_diagnosis_other STRING OPTIONS(description="Additional name of the organ site (single) within the body; may be referenced in primary site of disease, surgical intervention, or extent of disease documentation. NCI CDE: 2967298"),
  metastatic_site_at_diagnosis STRING OPTIONS(description="Information related to established or verified identification by signs and symptoms of malignant tumor spread from an original (primary) site to another location in the body._Name of the organ site (single) within the body; may be referenced in primary site of disease, surgical intervention, or extent of disease documentation. NCI CDE: 2967298"),
  ss18_ssx_testing_method STRING OPTIONS(description="Text term that represents the laboratory test method used to obtain the result of the laboratory test for the SS18-SSX fusion protein expression status for the synovial sarcoma. NCI CDE: 3733517"),
  ss18_ssx_fusion_status STRING OPTIONS(description="Text term that represents the result of the laboratory test for the SS18-SSX fusion protein expression status for the synovial sarcoma. NCI CDE: 3733516"),
  specific_tumor_total_necrosis_percent STRING OPTIONS(description="specific tumor total necrosis percent"),
  leiomyosarcoma_histologic_subtype STRING OPTIONS(description="leiomyosarcoma histologic subtype"),
  metastatic_neoplasm_confirmed STRING OPTIONS(description="Yes/no indicator to ask if identification of malignant tumor spread from an original (primary) site to another location in the body has been established or verified. NCI CDE: 65384"),
  local_disease_recurrence STRING OPTIONS(description="Yes/no indicator to specify whether local recurrence of the disease has been detected. NCI CDE: 62652"),
  days_to_well_differentiated_liposarcoma_primary_dx STRING OPTIONS(description="Numeric value that represents the day of the primary diagnosis of well differentiated liposarcoma."),
  mpnst_neurofibromatosis STRING OPTIONS(description="Mpnst neurofibromatosis"),
  mpnst_exisiting_plexiform_neurofibroma STRING OPTIONS(description="Mpnst exisiting plexiform neurofibroma"),
  mpnst_nf1_genetic_testing STRING OPTIONS(description="Mpnst nf1 genetic testing"),
  mpnst_specific_mutations STRING OPTIONS(description="Mpnst specific mutations"),
  well_differentiated_liposarcoma_primary_dx STRING OPTIONS(description="Time interval from the date of primary diagnosis of well differentiated liposarcoma to the date of initial pathologic diagnosis, represented as a calculated number of days."),
  leiomyosarcoma_major_vessel_involvement STRING OPTIONS(description="Text term to represent the category of major blood vessel involved in leiomyosarcoma. NCI CDE: 3243330"),
  discontiguous_lesion_count STRING OPTIONS(description="An operation in which a term denies or inverts the meaning of another term or construction._Touching or very close together._(LEE-zhun) An area of abnormal tissue change._Quantity; how much there is of something that you can measure._the quantity of specified lesions. NCI CDE: 3162604"),
  mpnst_neurofibromatosis_heredity STRING OPTIONS(description="Mpnst neurofibromatosis heredity"),
  maximum_tumor_dimension STRING OPTIONS(description="Maximum tumor dimension"),
  alcoholic_exposure_category STRING OPTIONS(description="Category to describe the patient's current level of alcohol use as self-reported by the patient. NCI CDE: 3457767"),
  planned_surgery_status STRING OPTIONS(description="Indicator and/or text term to describe the intent to use a surgical procedure to treat the cancer. NCI CDE: 3440231"),
  esophageal_tumor_involvement_site STRING OPTIONS(description="Text term that describes the portion of the esophagus divided in thirds in which the tumor involvement is located. NCI CDE: 3295806"),
  esophageal_tumor_cental_location STRING OPTIONS(description="Text term that describes the portion of the esophagus divided in thirds in which the tumor is centered. NCI CDE: 3295805"),
  lymph_node_metastasis_radiographic_evidence STRING OPTIONS(description="Indicator to signify whether or not radiographic evidence exists to support the finding of lymph node metastasis. NCI CDE: 3440228"),
  days_to_pancreatitis_onset STRING OPTIONS(description="Numeric value to represent the day that the patient was diagnosed with clinical chronic pancreatitis."),
  days_to_diabetes_onset STRING OPTIONS(description="Numeric value to represent the day that the patient was diagnosed with diabetes."),
  adenocarcinoma_invasion STRING OPTIONS(description="Yes/No indicator about adenocarcinoma invasion."),
  surgery_performed_type STRING OPTIONS(description="The type of surgery performed."),
  columnar_metaplasia_present STRING OPTIONS(description="Indicator to signify whether or not esophageal columnar metaplasia is present. NCI CDE: 3440218"),
  relative_cancer_type STRING OPTIONS(description="Text that describes which and how many of the patient's first degree relatives have been diagnosed with pancreatic cancer. NCI CDE: 3287339"),
  amt_alcohol_consumption_per_day STRING OPTIONS(description="Numeric value that represents on the days when a person drank, on average, about how many drinks they had."),
  columnar_mucosa_goblet_cell_present STRING OPTIONS(description="Indicator to signify whether or not goblet cells were present in esophageal columnar mucosa. NCI CDE: 3440219"),
  history_of_chronic_pancreatitis STRING OPTIONS(description="History of chronic pancreatitis"),
  history_of_diabetes STRING OPTIONS(description="HIstory of diabetes"),
  goblet_cells_present STRING OPTIONS(description="Goblet cells present"),
  history_of_esophageal_cancer STRING OPTIONS(description="History of esophageal cancer"),
  histologic_grading_tier_category STRING OPTIONS(description="Term to describe the number of levels or 'tiers' in the system used to describe the cellular histologic grade in a tissue specimen. NCI CDE: 3385981"),
  columnar_mucosa_dysplasia STRING OPTIONS(description="Text term to describe the amount of dysplasia found within the benign esophageal columnar mucosa. NCI CDE: 3440917"),
  number_of_relatives_diagnosed STRING OPTIONS(description="Number of relatives diagnosed with cancer"),
  state_province_of_procurement STRING OPTIONS(description="State province of procurement"),
  treatment_prior_to_surgery STRING OPTIONS(description="Text term to describe the kind of treatment given to an individual prior to surgery."),
  initial_diagnosis_by STRING OPTIONS(description="Initial diagnosis by"),
  surgery_performed_type_other STRING OPTIONS(description="Surgery performed type other"),
  country_of_birth STRING OPTIONS(description="The country in which a person was born"),
  disease_detected_on_screening STRING OPTIONS(description="Disease detected on screening"),
  history_pheo_or_para_include_benign STRING OPTIONS(description="History pheo or para include benign"),
  outside_adrenal STRING OPTIONS(description="Text term to describe any tumor related to the specimen that is outside of the adrenal glands. NCI CDE: 3693063"),
  history_pheo_or_para_anatomic_site STRING OPTIONS(description="Text field to describe the anatomic site of the prior pheochromocytoma or paraganglioma. NCI CDE: 3693062"),
  family_member_relationship_type STRING OPTIONS(description="The subgroup that describes the state of connectedness between members of the unit of society organized around kinship ties. NCI CDE: 2690165"),
  post_op_ablation_embolization_tx STRING OPTIONS(description="Post op ablation embolization tx"),
  days_to_pre_orchi_serum_test STRING OPTIONS(description="Time interval in days from the date of the patient's initial pathologic diagnosis to the date that the pre-orchiectomy serum marker tests were obtained."),
  post_orchi_hcg STRING OPTIONS(description="Post orchi hcg"),
  bilateral_diagnosis_timing_type STRING OPTIONS(description="Text term to describe the timing of the diagnosis of bilateral malignant testicular germ cell tumor. NCI CDE: 3901753"),
  post_orchi_ldh STRING OPTIONS(description="Post orchi ldh"),
  testis_tumor_microextent STRING OPTIONS(description="Testis tumor microextent"),
  undescended_testis_corrected STRING OPTIONS(description="Text term to signify whether or not the undescended testis was corrected."),
  post_orchi_lh STRING OPTIONS(description="Post orchi lh"),
  post_orchi_lymph_node_dissection STRING OPTIONS(description="Indicator that signifies whether or not the retroperitoneal lymph nodes were dissected after orchiectomy and if so, whether it was before or after chemotherapy was given. NCI CDE: 3953323"),
  post_orchi_testosterone STRING OPTIONS(description="Numerical representation of the amount of testosterone in serum measured after orchiectomy. NCI CDE: 3901839"),
  serum_markers STRING OPTIONS(description="Serum tumor markers (S)"),
  undescended_testis_corrected_age STRING OPTIONS(description="Numeric and text description for the approximate age in months or years at which an individual had an undescended testis corrected."),
  undescended_testis_method_left STRING OPTIONS(description="Text term to describe the method by which the left undescended testis was corrected. NCI CDE: 4340449"),
  relation_testicular_cancer STRING OPTIONS(description="Text term that describes an individual's relationship to a biological relative who has been diagnosed with malignant testicular germ cell tumor. NCI CDE: 3901751"),
  postoperative_tx STRING OPTIONS(description="Name of postoperative treatment."),
  testis_tumor_macroextent STRING OPTIONS(description="Testis tumor macroextent"),
  synchronous_tumor_histology_pct STRING OPTIONS(description="Synchronous tumor histology pct"),
  pre_orchi_afp STRING OPTIONS(description="Pre orchi afp"),
  pre_orchi_hcg STRING OPTIONS(description="Pre orchi hcg"),
  pre_orchi_ldh STRING OPTIONS(description="Pre orchi ldh"),
  pre_orchi_lh STRING OPTIONS(description="Prevorchi lh"),
  pre_orchi_testosterone STRING OPTIONS(description="Pre orchi testosterone"),
  synchronous_tumor_histology_type STRING OPTIONS(description="Synchronous tumor histology type"),
  relative_family_cancer_hx_text STRING OPTIONS(description="Relative family cancer hx text"),
  days_to_post_orchi_serum_test STRING OPTIONS(description="Numeric value to represent the day of the serum tumor markers after orchiectomy."),
  undescended_testis_method_right STRING OPTIONS(description="Text term to describe the method by which the right undescended testis was corrected. NCI CDE: 4340450"),
  testis_tumor_macroextent_other STRING OPTIONS(description="Testis tumor macroextent other"),
  days_to_bilateral_tumor_dx STRING OPTIONS(description="Time interval from the date of initial pathologic diagnosis to the date of bilateral testicular cancer diagnosis, represented as a calculated number of day"),
  level_of_non_descent STRING OPTIONS(description="Level of non descent"),
  post_orchi_afp STRING OPTIONS(description="Post orchi afp"),
  intratubular_germ_cell_neoplasm STRING OPTIONS(description="Intratubular germ cell neoplasm"),
  igcccg_stage STRING OPTIONS(description="Igcccg stage"),
  history_of_undescended_testis STRING OPTIONS(description="History of undescended testis"),
  molecular_test_result STRING OPTIONS(description="Term to describe an abnormal result of molecular analysis. NCI CDE: 3121628"),
  history_hypospadias STRING OPTIONS(description="Text term to signify whether or not an individual has a history of a congenital abnormality in which the external urethral orifice is on the underside of the penis. NCI CDE: 3896751"),
  history_fertility STRING OPTIONS(description="Text term to describe an individual's capacity to conceive or to induce conception. NCI CDE: 3896771"),
  histological_percentage STRING OPTIONS(description="Text field to capture the numerical percentage for the confirmed histologic diagnosis of the submitted tumor, based on the pathology review. NCI CDE: 3729998"),
  first_treatment_success STRING OPTIONS(description="First treatment success"),
  family_history_testicular_cancer STRING OPTIONS(description="Yes/no indicator of family history of testicular cancer"),
  family_history_other_cancer STRING OPTIONS(description="The yes/no indicator of family history of type of cancer of that is not already mentioned or specified in a list of values."),
  masaoka_stage STRING OPTIONS(description="Extent of the thymoma tumor using the Masaoka Staging system. NCI CDE: 3952848"),
  history_myasthenia_gravis STRING OPTIONS(description="Indicator to signify whether or not the patient has a history of myasthenia gravis. NCI CDE: 3950458"),
  section_myasthenia_gravis STRING OPTIONS(description="Section myasthenia gravis"),
  new_neoplasm_occurrence_anatomic_site_text STRING OPTIONS(description="Text to describe the anatomic location of the return of tumor after treatment, at a specific distant metastatic location. NCI CDE: 3128033"),
  percent_tumor_sarcomatoid STRING OPTIONS(description="Percent value of tumor that is sarcomatoid in renal cell carcinoma."),
  presence_of_sarcomatoid_features STRING OPTIONS(description="Presence of sarcomatoid features"),
  tmem127 STRING OPTIONS(description="tmem127"),
  therapeutic_mitotane_lvl_recurrence STRING OPTIONS(description="Therapeutic mitotane lvl recurrence"),
  therapeutic_mitotane_lvl_macroscopic_residual STRING OPTIONS(description="Therapeutic mitotane lvl macroscopic residual"),
  therapeutic_mitotane_levels_achieved STRING OPTIONS(description="Therapeutic mitotane levels achieved"),
  metastatic_neoplasm_initial_diagnosis_anatomic_site STRING OPTIONS(description="Metastatic neoplasm initial diagnosis anatomic site"),
  mitoses_count STRING OPTIONS(description="Numeric representation of the mitoses count per 50 high power fields. NCI CDE: 3646391"),
  mitotane_therapy STRING OPTIONS(description="Indicator to signify whether or not mitotane therapy was given. NCI CDE: 3646372"),
  mitotane_therapy_adjuvant_setting STRING OPTIONS(description="Mitotane therapy adjuvant setting"),
  mitotane_therapy_for_macroscopic_residual_disease STRING OPTIONS(description="Mitotane therapy for macroscopic residual disease"),
  mitotic_rate STRING OPTIONS(description="The numeric response that indicates the rate measured for the number of mitoses identified under the microscope in malignant neoplasm. NCI CDE: 6941877"),
  sinusoid_invasion STRING OPTIONS(description="Sinusoid invasion"),
  therapeutic_mitotane_lvl_progression STRING OPTIONS(description="Therapeutic mitotane lvl progression"),
  excess_adrenal_hormone_diagnosis_method_type STRING OPTIONS(description="Text term to describe the method by which the diagnosis of adrenal hormone excess was made. NCI CDE: 3646387"),
  molecular_analysis_performed_indicator STRING OPTIONS(description="Text indicator to signify whether any molecular testing was performed for an individual. NCI CDE: 3121565"),
  excess_adrenal_hormone_history_type STRING OPTIONS(description="Text term that represents the kind of adrenal hormone excess in the patient's history. NCI CDE: 3646386"),
  necrosis STRING OPTIONS(description="The indication that the histologic feature of tumor necrosis is present. NCI CDE: 6790121"),
  sdhd STRING OPTIONS(description="The text response indicating whether a mutation was identified while performing the SDHD gene mutation analysis. NCI CDE: 6790163"),
  sdhc STRING OPTIONS(description="The text response indicating whether a mutation was identified while performing the SDHC gene mutation analysis. NCI CDE: 6790162"),
  nuclear_grade_III_IV STRING OPTIONS(description="Nuclear grade III IV"),
  sdhb STRING OPTIONS(description="The text response indicating whether a mutation was identified while performing the SDHB gene mutation analysis. NCI CDE: 6790161"),
  sdhaf2_sdh5 STRING OPTIONS(description="sdhaf2 sdh5"),
  sdha STRING OPTIONS(description="The text response indicating whether a mutation was identified while performing the SDHA gene mutation analysis."),
  atypical_mitotic_figures STRING OPTIONS(description="Atypical mitotic figures"),
  ct_scan_findings STRING OPTIONS(description="Text term to describe the result of a computed tomography diagnostic procedure."),
  ret STRING OPTIONS(description="RET Oncogene Mutation Status."),
  cytoplasm_presence_less_than_equal_25_percent STRING OPTIONS(description="Percentage expressing the quantity of cancer cells identified by dye applied to the cytoplasm of a cell during microscopic assessment of a tissue sample by a specialist in cellular function."),
  weiss_venous_invasion STRING OPTIONS(description="Weiss venous invasion"),
  weiss_score STRING OPTIONS(description="Numeric value to represent the sum of the individual scores for each Weiss criterion assessment to determine the overall Weiss score. NCI CDE: 3648744"),
  vhl STRING OPTIONS(description="The text response indicating whether a germ-line mutation was identified while performing the VHL gene mutation analysis. NCI CDE: 6790146"),
  invasion_of_tumor_capsule STRING OPTIONS(description="Invasion of tumor capsule"),
  diffuse_architecture STRING OPTIONS(description="Diffuse architecture"),
  serum_mesothelin_lower_limit STRING OPTIONS(description="Numerical quantity measured that is the bottom value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for serum mesothelin result. NCI CDE: 3629986"),
  asbestos_exposure_type STRING OPTIONS(description="Text term that describes a kind of exposure to asbestos. NCI CDE: 3629989"),
  pleurodesis_performed_90_days STRING OPTIONS(description="Indicator to signify whether or not pleurodesis was performed 90 days prior to cancer sample procurement. NCI CDE: 3646080"),
  mesothelioma_detection_method STRING OPTIONS(description="Mesothelioma detection method"),
  history_asbestos_exposure STRING OPTIONS(description="History asbestos exposure"),
  pleurodesis_performed_prior STRING OPTIONS(description="Indicator to signify whether or not pleurodesis was performed prior to cancer sample procurement. NCI CDE: 3646078"),
  family_history_cancer_type STRING OPTIONS(description="Text that describes which and how many of the patient's first degree relatives have been diagnosed with cancer."),
  family_history_cancer_type_other STRING OPTIONS(description="Text that describes which and how many of the patient's first degree relatives have been diagnosed with another cancer that is not already mentioned or specified. NCI CDE: 3287343"),
  asbestos_exposure_age STRING OPTIONS(description="Numeric representation of the age of a person when they were first exposed to asbestos. NCI CDE: 3629991"),
  serum_mesothelin_prior_tx STRING OPTIONS(description="Serum mesothelin prior tx"),
  asbestos_exposure_years STRING OPTIONS(description="Numeric representation of the length of time in years that a person was exposured to asbestos. NCI CDE: 3629992"),
  serum_mesothelin_upper_limit STRING OPTIONS(description="Numerical quantity measured that is the highest value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for serum mesothelin result. NCI CDE: 3629987"),
  asbestos_exposure_source STRING OPTIONS(description="Text term that describes the origination of an initial exposure to asbestos. NCI CDE: 3629990"),
  suv_of_pleura_max STRING OPTIONS(description="suv of pleura max"),
  primary_occupation STRING OPTIONS(description="Primary occupation of the participant for most of their adult employment. NCI CDE: 5714"),
  primary_occupation_years_worked STRING OPTIONS(description="Primary occupation years worked"),
  primary_occupation_other STRING OPTIONS(description="Primary occupation other"),
  creatinine_norm_range_lower STRING OPTIONS(description="Laboratory procedure creatinine result lower limit of normal value"),
  creatinine_norm_range_upper STRING OPTIONS(description="Laboratory procedure creatinine result upper limit of normal value"),
  asbestos_exposure_age_last STRING OPTIONS(description="Numeric representation of the age of a person when they experienced the final exposure to asbestos. NCI CDE: 3629993"),
  creatinine_prior_tx STRING OPTIONS(description="Creatinine prior tx"),
  tumor_basal_diameter STRING OPTIONS(description="Numeric value in millimeters for the lowest layer of a tumor. NCI CDE: 3870453"),
  tumor_basal_diameter_mx STRING OPTIONS(description="Numeric value in millimeters for the lowest layer of a tumor."),
  metastatic_site STRING OPTIONS(description="Text term that describes the anatomic site of the metastatic disease."),
  tumor_thickness STRING OPTIONS(description="Tumor thickness value"),
  microvascular_density_mvd STRING OPTIONS(description="Numeric representation of the microvascular density (MVD) of the tissue specimen. NCI CDE: 3874272"),
  tumor_shape_pathologic_clinical STRING OPTIONS(description="Text term to represent the description of the shape of a tumor determined by clinical or pathological techniques."),
  tumor_infiltrating_lymphocytes STRING OPTIONS(description="Description of degree of lymphocytic infiltration surrounding and disrupting tumor cells of the vertical growth phase in a cutaneous melanoma. NCI CDE: 2431591"),
  tumor_morphology_percentage STRING OPTIONS(description="Numerical percentage range for the confirmed histologic diagnosis of the submitted tumor, based on the pathology review."),
  tumor_thickness_measurement STRING OPTIONS(description="Text term that represents the technique used to measure the tumor thickness. NCI CDE: 3870440"),
  tumor_infiltrating_macrophages STRING OPTIONS(description="Text term that describes the qualitative amount of non-neoplastic macrophages that infiltrate a tumor. NCI CDE: 3874291"),
  pet_ct_standardized_values STRING OPTIONS(description="Standarized values of the PET/CT Exam."),
  eye_color STRING OPTIONS(description="Text term that represents the color of an individual's eyes. NCI CDE: 3870394"),
  other_metastatic_site STRING OPTIONS(description="Text term to signify the presence of anatomic sites of metastatic disease that are different than the one(s) previously specified or mentioned [Manually-curated] NCI CDE: 2760050"),
  extravascular_matrix_patterns STRING OPTIONS(description="Extravascular matrix patterns"),
  histological_type_1 STRING OPTIONS(description="Histological type 1"),
  extranocular_nodule_size STRING OPTIONS(description="Extranocular nodule size"),
  extrascleral_extension STRING OPTIONS(description="Indicator to signify whether or not the uveal melanoma has spread beyond the sclera. NCI CDE: 3874292"),
  gene_expression_profile STRING OPTIONS(description="Text term that represents the class designation resulting from gene expression profiling. NCI CDE: 3870395"),
  cytogenetic_abnormality STRING OPTIONS(description="An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Indicator of Yes, No, Unknown, Not Done, or Not Applicable to a question.[manually curated] NCI CDE: 2760479"),
  result_of_immunophenotypic_analysis STRING OPTIONS(description="Result of immunophenotypic analysis"),
  prior_immunosuppressive_therapy_other STRING OPTIONS(description="Prior immunosuppressive therapy other"),
  prior_immunosuppressive_therapy_type STRING OPTIONS(description="Text term to describe the immunosuppressive therapy used to treat a patient's prior immunological disease. NCI CDE: 3233638"),
  prior_infectious_disease STRING OPTIONS(description="Text term used to identify a patient's prior history of relevant infectious diseases. NCI CDE: 3233642"),
  igk_genotype_results_1 STRING OPTIONS(description="Text term to define the results of IgK genotype testing. NCI CDE: 3233565"),
  immunophenotypic_analysis_method STRING OPTIONS(description="The method used for immunophenotyping._to perform immunophenotype tests on pathology samples. NCI CDE: 64540"),
  igk_genotype_results STRING OPTIONS(description="igk genotype results"),
  bone_marrow_biopsy_done STRING OPTIONS(description="Yes/no indicator to ask if a bone marrow biopsy procedure was performed."),
  bone_marrow_involvement STRING OPTIONS(description="Yes/no/unknown/not available indicator related to involvement of the patient's bone marrow by disease. NCI CDE: 3296100"),
  bone_marrow_involvement_1 STRING OPTIONS(description="Yes/no indicator to ask if the bone marrow has been affected by the patient's disease. NCI CDE: 2180550"),
  prior_infectious_disease_other STRING OPTIONS(description="Text to describe a patient's other prior history of relevant infectious diseases not specified elsewhere. NCI CDE: 3233643"),
  ebv_positive_malignant_cells_percent STRING OPTIONS(description="Numeric value to represent the percentage of EBV positive malignant cells. NCI CDE: 3233649"),
  b_lymphocyte_genotyping_method_1 STRING OPTIONS(description="The method used to perform B-Cell genotyping. NCI CDE: 3233449"),
  prior_immunologic_disease_type STRING OPTIONS(description="Text term describing a patient's prior medical history as related to immunological diseases. NCI CDE: 3233628"),
  igh_genotype_results_1 STRING OPTIONS(description="Text term to define the results of IgH genotype testing. NCI CDE: 3233560"),
  b_lymphocyte_genotyping_method STRING OPTIONS(description="The method used to perform B-Cell genotyping. NCI CDE: 3233449"),
  prior_immunologic_disease_other STRING OPTIONS(description="Text to describe a patient's other prior medical history as related to immunological diseases not already specified or mentioned. NCI CDE: 3233629"),
  maximum_tumor_bulk_anatomic_location STRING OPTIONS(description="Text description to represent the anatomic location (nodal or extranodal) of the maximum tumor bulk. NCI CDE: 3233300"),
  immunophenotypic_analysis_results STRING OPTIONS(description="Text term to define the results of immunophenotypic analysis. NCI CDE: 3234626"),
  maximum_tumor_bulk_anatomic_site STRING OPTIONS(description="Text term to represent the anatomic location (including nodal or extranodal site) of the maximum tumor bulk. NCI CDE: 3639616"),
  immunophenotypic_analysis_test STRING OPTIONS(description="Immunophenotypic analysis test"),
  extranodal_sites_involvement_number STRING OPTIONS(description="Numeric value to represent the number of extranodal sites involved clinically and/or pathologically with malignant lymphoma at the time of initial diagnosis. NCI CDE: 3233242"),
  immunophenotypic_analysis_tested STRING OPTIONS(description="Immunophenotypic analysis tested indicator."),
  ebv_status_malignant_cells_method STRING OPTIONS(description="The method used to perform diagnostic testing for the presence of EBV positive malignant cells. NCI CDE: 3233656"),
  percent_ebv_positive_malignant_cells STRING OPTIONS(description="Numeric value to represent the percentage of EBV positive malignant cells."),
  tumor_resected_max_dimension STRING OPTIONS(description="Tumor resected maximum dimension."),
  immunophenotypic_analysis_methodology STRING OPTIONS(description="immunophenotypic analysis methodology"),
  igh_genotype_results STRING OPTIONS(description="igh genotype results"),
  ebv_diagnostic_methodology STRING OPTIONS(description="ebv diagnostic methodology"),
  follicular_component_percent STRING OPTIONS(description="Percentage of follicular component."),
  abnormality_tested_methodology STRING OPTIONS(description="Methodology of cytogenetic abnormality test, examples: gain, loss, translocation, etc."),
  nodal_anatomic_site STRING OPTIONS(description="Nodal anatomic site"),
  histology_of_bone_marrow_sample STRING OPTIONS(description="Histology of bone marrow sample"),
  abnormality_tested_methodology_1 STRING OPTIONS(description="Methodology of cytogenetic abnormality test, examples: gain, loss, translocation, etc."),
  ldh_upper_limit STRING OPTIONS(description="ldh upper limit"),
  number_of_involved_extranodal_sites STRING OPTIONS(description="Numeric value to represent the number of extranodal sites involved clinically and/or pathologically with malignant lymphoma at the time of initial diagnosis."),
  extranodal_disease_involvement_site STRING OPTIONS(description="Description of the anatomic location of extranodal disease involvement at the time of initial diagnosis of malignant lymphoma. NCI CDE: 3288482"),
  ebv_antibody_status STRING OPTIONS(description="The result of a test to detect the presence of Epstein-Barr virus antibody in a patient. NCI CDE: 2003961"),
  extranodal_disease_involvement_site_other STRING OPTIONS(description="Extranodal disease involvement site other"),
  genetic_abnormality_tested_other STRING OPTIONS(description="Text term to identify other genetic abnormalities not otherwise specified for which a patient was tested. NCI CDE: 3234685"),
  genetic_abnormality_tested_1 STRING OPTIONS(description="Text term to identify specific genetic abnormalities for which a patient was tested. NCI CDE: 3234675"),
  genetic_abnormality_tested STRING OPTIONS(description="Genetic abnormality tested"),
  genetic_abnormality_results_other STRING OPTIONS(description="Text term that describes a genetic abnormality test result that was not previously mentioned or specified. NCI CDE: 4459354"),
  genetic_abnormality_results STRING OPTIONS(description="Text term to define the results of genetic testing. NCI CDE: 3234680"),
  percentage_of_follicular_component STRING OPTIONS(description="Numeric value to represent the percentage of the follicular component within the diffuse large B-cell lymphoma."),
  pet_scan_results STRING OPTIONS(description="PET scan results."),
  other_genetic_abnormality_tested STRING OPTIONS(description="Text term to identify other genetic abnormalities not otherwise specified for which a patient was tested."),
  epstein_barr_viral_status STRING OPTIONS(description="A finding based on the viral load assay of the Epstein-Barr virus which may be an indicator of disease status. NCI CDE: 7062938"),
  lymph_node_involvement_site STRING OPTIONS(description="Free text field to identify the lymph nodes which are anatomic sites of disease. NCI CDE: 61293"),
  mib1_positive_percentage_range STRING OPTIONS(description="Numeric value to represent the percentage range of MIB-1 positive cells thru immunophenotypic analysis. NCI CDE: 3233414"),
  mib1_positive_percentage_range_1 STRING OPTIONS(description="Numeric value to represent the percentage range of MIB-1 positive cells thru immunophenotypic analysis. NCI CDE: 3233414"),
  genetic_abnormality_method_other STRING OPTIONS(description="Text term that describes a genetic abnormality test method that was not previously mentioned or specified. NCI CDE: 4459355"),
  extranodal_involvment_site_other STRING OPTIONS(description="Name of other anatomic site of extranodal disease."),
  ldh_lab_value STRING OPTIONS(description="ldh lab value"),
  hiv_positive_status STRING OPTIONS(description="HIV positive status"),
  ldh_level STRING OPTIONS(description="Information related to the result of the medical procedure that involves testing a sample of blood for lactic dehydrogenase, a family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis._A position on a scale measuring intensity, quality, or amount._A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. NCI CDE: 6323378"),
  ldh_norm_range_upper STRING OPTIONS(description="The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for lactate dehydrogenase (units not specified). NCI CDE: 2597015"),
  abnormality_tested_results_1 STRING OPTIONS(description="Results of cytogenetic abnormality test, examples: gain, loss, translocation, etc."),
  abnormality_tested_results STRING OPTIONS(description="Results of cytogenetic abnormality test, examples: gain, loss, translocation, etc."),
  genetic_abnormality_method STRING OPTIONS(description="Text term to classify the testing method used to determine the genetic abnormality. NCI CDE: 3234684"),
  bone_marrow_sample_histology STRING OPTIONS(description="Bone marrow sample histology."),
  albumin_result_upper_limit STRING OPTIONS(description="Numeric laboratory value representing the upper level of the normal range of values for Albumin in peripheral blood serum. NCI CDE: 2004086"),
  vascular_tumor_cell_type STRING OPTIONS(description="Text term that represents the type of vascular tumor invasion. NCI CDE: 3168001"),
  albumin_result_lower_limit STRING OPTIONS(description="Numeric laboratory value representing the lower level of the normal range of values for Albumin in peripheral blood serum used to comparatively reference the patient's lab result NCI CDE: 2004085"),
  albumin_result_specified_value STRING OPTIONS(description="Value of a lab test used to determine the albumin level in the blood. NCI CDE: 58274"),
  platelet_result_upper_limit STRING OPTIONS(description="Top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for peripheral platelet count laboratory result or other quantitative parameter (units not specified). NCI CDE: 2596499"),
  intern_norm_ratio_upper_limit STRING OPTIONS(description="Upper limit of normal of the International Normalization Ratio value. NCI CDE: 2190394"),
  cholangitis_tissue_evidence STRING OPTIONS(description="Text term to describe the kind of evidence present in adjacent tissue related to primary sclerosing cholangitis (PSC). NCI CDE: 3916091"),
  relative_family_cancer_history STRING OPTIONS(description="Yes/no/unknown indicator that asks whether any blood relatives have ever been diagnosed with cancer. NCI CDE: 2691192"),
  platelet_result_lower_limit STRING OPTIONS(description="The lower limit of normal for peripheral platelet laboratory value. NCI CDE: 2003885"),
  hist_hepato_carcinoma_risk STRING OPTIONS(description="Text term to represent the name of the primary condition that increases a person's chance of developing a malignant tumor of the hepatocytes"),
  hist_hepato_carc_fact STRING OPTIONS(description="Text term to represent the name of the primary condition that increases a person's chance of developing a malignant tumor of the hepatocytes. NCI CDE: 3171846"),
  cancer_first_degree_relative STRING OPTIONS(description="Numeric value that represents the number of first degree relatives (parent, sibling, and/or child) diagnosed with cancer. NCI CDE: 3171640"),
  creatinine_lower_level STRING OPTIONS(description="Lowest value of the range of statistical characteristics that are supposed to represent accepted standard for patient's sample of blood for creatinine, the breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function."),
  prothrombin_time_result_value STRING OPTIONS(description="Numeric laboratory value of the prothrombin coagulation time in peripheral blood. NCI CDE: 2459694"),
  ca_19_9_level_upper STRING OPTIONS(description="The number that represents the reported high limit of the cancer antigen 19-9 test reference range."),
  ca_19_9_level_lower STRING OPTIONS(description="The number that represents the reported low limit of the cancer antigen 19-9 test reference range."),
  ca_19_9_level STRING OPTIONS(description="CA 19-9 level in the blood."),
  creatinine_upper_limit STRING OPTIONS(description="Numeric laboratory value representing the upper level of the normal range of values for Creatinine in peripheral blood serum. NCI CDE: 2004064"),
  surgical_procedure_name STRING OPTIONS(description="The name of surgical procedure. NCI CDE: 7063813"),
  creatinine_value_in_mg_dl STRING OPTIONS(description="A value which captures the amount of Creatinine in the blood measured in milligrams per deciliter (mg/dL)"),
  bilirubin_lower_limit STRING OPTIONS(description="Value, units of measure not specified, of the lowest value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result related to testing a sample of blood for direct bilirubin, bilirubin which reacts with sulfanilic acid at acidic pH to produce a red colored complex and is bound to glucuronide to form conjugated bilirubin (direct bilirubin) and is measured a colorimetric method. NCI CDE: 3294386"),
  total_bilirubin_upper_limit STRING OPTIONS(description="Numeric laboratory value (units not specified) for the procedure that involves testing or manipulating a sample of blood in a laboratory setting for total bilirubin, a breakdown product of hemoglobin, liver lab. NCI CDE: 2004060"),
  platelet_result_count STRING OPTIONS(description="The absolute platelet count."),
  fibrosis_ishak_score STRING OPTIONS(description="The score or group of scores as described by Dr. Kamal G. Ishak and colleagues to assess the histopathologic degree of liver damage. NCI CDE: 3182621"),
  fetoprotein_outcome_value STRING OPTIONS(description="Numerical quantity measured for a laboratory result for alpha fetoprotein derived from cerebrospinal fluid. NCI CDE: 3385649"),
  fetoprotein_outcome_upper_limit STRING OPTIONS(description="Numerical quantity measured that is the top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter for alpha fetoprotein (a protein normally produced by a developing fetus). NCI CDE: 2932064"),
  fetoprotein_outcome_lower_limit STRING OPTIONS(description="Numerical quantity measured that is the bottom value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter for alpha fetoprotein (a protein normally produced by a developing fetus). NCI CDE: 3171861"),
  inter_norm_ratio_lower_limit STRING OPTIONS(description="Lower limit of normal of the International Normalization Ratio value. NCI CDE: 2799755"),
  family_cancer_type_txt STRING OPTIONS(description="The  type of family relative that has a history of cancer."),
  bilirubin_upper_limit STRING OPTIONS(description="Numeric laboratory value representing the upper level of the normal range of values for direct bilirubin, a breakdown product of hemoglobin. NCI CDE: 3233756"),
  days_to_last_known_alive STRING OPTIONS(description="Numeric value to represent the day of which the patient's survival status of alive could be verified.")
)
OPTIONS(
  friendly_name="PanCancer Clinical With Patient Follow-up",
  description="Data loaded from the PanCancer Atlas initiative on the GDC in April 2018. Clinical information about patient cases in the TCGA project.  \n\nMore details:  https://gdc.cancer.gov/about-data/publications/pancanatlas file: clinical_PANCAN_patient_with_followup.tsv  \n\nand https://www.synapse.org/#!Synapse:syn4983466.1. \n\nFor data filtered by the barcode white list, table Filtered_clinical_PANCAN_patient_with_followup is recommended.",
  labels=[("category", "clinical_biospecimen_data"), ("status", "current"), ("access", "open"), ("source_0", "gdc"), ("data_type", "clinical_data"), ("program", "pancancer_atlas"), ("reference_genome", "hg19"), ("source_1", "literature")]
);

INSERT INTO `isb-cgc-bq.pancancer_atlas.Original_clinical_PANCAN_patient_with_followup` (bcr_patient_uuid, bcr_patient_barcode, acronym, gender, vital_status, days_to_birth, days_to_death, days_to_last_followup, days_to_initial_pathologic_diagnosis, age_at_initial_pathologic_diagnosis, icd_10, tissue_retrospective_collection_indicator, icd_o_3_histology, tissue_prospective_collection_indicator, history_of_neoadjuvant_treatment, icd_o_3_site, tumor_tissue_site, new_tumor_event_after_initial_treatment, radiation_therapy, race, project_code, prior_dx, disease_code, ethnicity, informed_consent_verified, person_neoplasm_cancer_status, patient_id, year_of_initial_pathologic_diagnosis, histological_type, tissue_source_site, form_completion_date, pathologic_T, pathologic_M, clinical_M, pathologic_N, system_version, pathologic_stage, stage_other, clinical_stage, clinical_T, clinical_N, extranodal_involvement, postoperative_rx_tx, primary_therapy_outcome_success, lymph_node_examined_count, primary_lymph_node_presentation_assessment, initial_pathologic_diagnosis_method, number_of_lymphnodes_positive_by_he, eastern_cancer_oncology_group, anatomic_neoplasm_subdivision, residual_tumor, histological_type_other, init_pathology_dx_method_other, karnofsky_performance_score, neoplasm_histologic_grade, height, weight, history_of_radiation_metastatic_site, days_to_patient_progression_free, days_to_first_response, days_to_first_partial_response, days_to_first_complete_response, days_to_tumor_progression, er_estimated_duration_response, er_disease_extent_prior_er_treatment, er_solid_tumor_response_documented_type, er_solid_tumor_response_documented_type_other, er_response_type, history_of_radiation_primary_site, history_prior_surgery_type, patient_progression_status, history_prior_surgery_type_other, history_prior_surgery_indicator, field, molecular_abnormality_results_other, molecular_abnormality_results, number_of_lymphnodes_positive_by_ihc, tobacco_smoking_history, number_pack_years_smoked, stopped_smoking_year, performance_status_scale_timing, laterality, targeted_molecular_therapy, year_of_tobacco_smoking_onset, anatomic_neoplasm_subdivision_other, patient_death_reason, tumor_tissue_site_other, menopause_status, age_began_smoking_in_years, margin_status, kras_gene_analysis_performed, kras_mutation_found, death_cause_text, lactate_dehydrogenase_result, days_to_sample_procurement, hbv_test, on_haart_therapy_at_cancer_diagnosis, hcv_test, prior_aids_conditions, on_haart_therapy_prior_to_cancer_diagnosis, kshv_hhv8_test, days_to_hiv_diagnosis, hiv_status, hiv_rna_load_at_diagnosis, cdc_hiv_risk_group, history_of_other_malignancy, history_immunosuppresive_dx, nadir_cd4_counts, history_relevant_infectious_dx_other, history_relevant_infectious_dx, cd4_counts_at_diagnosis, history_immunological_disease_other, hpv_test, history_immunosuppressive_dx_other, history_immunological_disease, lost_follow_up, venous_invasion, lymphatic_invasion, perineural_invasion_present, her2_erbb_method_calculation_method_text, her2_immunohistochemistry_level_result, breast_carcinoma_immunohistochemistry_pos_cell_score, distant_metastasis_present_ind2, her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text, breast_carcinoma_immunohistochemistry_progesterone_receptor_pos_finding_scale, breast_carcinoma_primary_surgical_procedure_name, er_level_cell_percentage_category, breast_carcinoma_progesterone_receptor_status, breast_carcinoma_surgical_procedure_name, breast_neoplasm_other_surgical_procedure_descriptive_text, er_detection_method_text, pos_finding_progesterone_receptor_other_measurement_scale_text, her2_erbb_pos_finding_cell_percent_category, her2_and_centromere_17_positive_finding_other_measurement_scale_text, pos_finding_metastatic_breast_carcinoma_estrogen_receptor_other_measuremenet_scale_text, metastatic_breast_carcinoma_progesterone_receptor_level_cell_percent_category, metastatic_breast_carcinoma_pos_finding_progesterone_receptor_other_measure_scale_text, fluorescence_in_situ_hybridization_diagnostic_procedure_chromosome_17_signal_result_range, first_recurrent_non_nodal_metastatic_anatomic_site_descriptive_text, first_nonlymph_node_metastasis_anatomic_site, immunohistochemistry_positive_cell_score, axillary_lymph_node_stage_method_type, axillary_lymph_node_stage_other_method_descriptive_text, metastatic_breast_carcinoma_progesterone_receptor_status, metastatic_breast_carcinoma_immunohistochemistry_pr_pos_cell_score, metastatic_breast_carcinoma_immunohistochemistry_er_pos_cell_score, metastatic_breast_carcinoma_lab_proc_her2_neu_immunohistochemistry_receptor_status, metastatic_breast_carcinoma_her2_neu_chromosone_17_signal_ratio_value, surgical_procedure_purpose_other_text, metastatic_breast_carcinoma_her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text, metastatic_breast_carcinoma_her2_erbb_pos_finding_cell_percent_category, breast_cancer_surgery_margin_status, metastatic_breast_carcinoma_her2_erbb_method_calculation_method_text, breast_carcinoma_estrogen_receptor_status, her2_neu_and_centromere_17_copy_number_analysis_input_total_number_count, pgr_detection_method_text, pos_finding_her2_erbb2_other_measurement_scale_text, breast_carcinoma_immunohistochemistry_er_pos_finding_scale, positive_finding_estrogen_receptor_other_measurement_scale_text, metastatic_breast_carcinoma_erbb2_immunohistochemistry_level_result, metastatic_breast_carcinoma_pos_finding_other_scale_measurement_text, her2_neu_chromosone_17_signal_ratio_value, cytokeratin_immunohistochemistry_staining_method_micrometastasis_indicator, metastatic_breast_carcinoma_estrogen_receptor_detection_method_text, metastatic_breast_carcinoma_lab_proc_her2_neu_in_situ_hybridization_outcome_type, metastatic_breast_carcinoma_pos_finding_her2_erbb2_other_measure_scale_text, lab_proc_her2_neu_immunohistochemistry_receptor_status, progesterone_receptor_level_cell_percent_category, metastatic_breast_carcinoma_estrogen_receptor_level_cell_percent_category, metastatic_breast_carcinoma_estrogen_receptor_status, lab_procedure_her2_neu_in_situ_hybrid_outcome_type, her2_neu_breast_carcinoma_copy_analysis_input_total_number, metastatic_breast_carcinoma_fluorescence_in_situ_hybridization_diagnostic_proc_centromere_17_signal_result_range, her2_neu_and_centromere_17_copy_number_metastatic_breast_carcinoma_analysis_input_total_number_count, her2_neu_metastatic_breast_carcinoma_copy_analysis_input_total_number, metastatic_breast_carcinoma_progesterone_receptor_detection_method_text, additional_pharmaceutical_therapy, additional_radiation_therapy, lymphovascular_invasion_present, pos_lymph_node_location_other, pos_lymph_node_location, location_in_lung_parenchyma, pulmonary_function_test_performed, pre_bronchodilator_fev1_fvc_percent, kras_mutation_result, post_bronchodilator_fev1_percent, pre_bronchodilator_fev1_percent, dlco_predictive_percent, egfr_mutation_performed, diagnosis, eml4_alk_translocation_result, egfr_mutation_result, post_bronchodilator_fev1_fvc_percent, eml4_alk_translocation_performed, eml4_alk_translocation_method, days_to_new_tumor_event_after_initial_treatment, hemoglobin_result, serum_calcium_result, platelet_qualitative_result, number_of_lymphnodes_positive, erythrocyte_sedimentation_rate_result, white_cell_count_result, malignant_neoplasm_metastatic_involvement_site, other_metastatic_involvement_anatomic_site, birth_control_pill_history_usage_category, alcohol_history_documented, frequency_of_alcohol_consumption, source_of_patient_death_reason, days_to_diagnostic_mri_performed, days_to_diagnostic_computed_tomography_performed, amount_of_alcohol_consumption_per_day, family_history_of_cancer, loss_expression_of_mismatch_repair_proteins_by_ihc_result, preoperative_pretreatment_cea_level, microsatellite_instability, number_of_loci_tested, history_of_colon_polyps, number_of_first_degree_relatives_with_cancer_diagnosis, number_of_abnormal_loci, circumferential_resection_margin, non_nodal_tumor_deposits, braf_gene_analysis_result, colon_polyps_present, kras_mutation_codon, braf_gene_analysis_performed, synchronous_colon_cancer_present, loss_expression_of_mismatch_repair_proteins_by_ihc, barretts_esophagus, city_of_procurement, reflux_history, country_of_procurement, antireflux_treatment_type, h_pylori_infection, hypertension, horm_ther, pln_pos_ihc, surgical_approach, pregnancies, diabetes, peritoneal_wash, pct_tumor_invasion, prior_tamoxifen_administered_usage_category, colorectal_cancer, total_aor_lnp, pln_pos_light_micro, total_pelv_lnp, total_pelv_lnr, aln_pos_light_micro, aln_pos_ihc, total_aor_lnr, post_surgical_procedure_assessment_thyroid_gland_carcinoma_status, metastatic_neoplasm_confirmed_diagnosis_method_text, metastatic_neoplasm_confirmed_diagnosis_method_name, prior_glioma, tumor_residual_disease, jewish_origin, distant_metastasis_anatomic_site, new_neoplasm_event_type, lymphnode_dissection_method_left, lymphnode_neck_dissection, egfr_amplication_status, hpv_status_by_ish_testing, presence_of_pathological_nodal_extracapsular_spread, p53_gene_analysis, hpv_status_by_p16_testing, lymphnode_dissection_method_right, eml4_alk_translocation_identified, egfr_mutation_identified, supratentorial_localization, mold_or_dust_allergy_history, motor_movement_changes, inherited_genetic_syndrome_found, seizure_history, asthma_history, first_diagnosis_age_asth_ecz_hay_fev_mold_dust, first_diagnosis_age_of_food_allergy, ldh1_mutation_found, tumor_location, ldh1_mutation_test_method, animal_insect_allergy_types, first_presenting_symptom, animal_insect_allergy_history, first_presenting_symptom_longest_duration, ldh1_mutation_tested, visual_changes, first_diagnosis_age_of_animal_insect_allergy, history_ionizing_rt_to_head, sensory_changes, food_allergy_history, mental_status_changes, hay_fever_history, preoperative_corticosteroids, preoperative_antiseizure_meds, family_history_of_primary_brain_tumor, inherited_genetic_syndrome_result, days_to_initial_score_performance_status_scale, food_allergy_types, headache_history, eczema_history, other_genotyping_outcome_lab_results_text, extrathyroid_carcinoma_present_extension_status, i_131_first_administered_dose, i_131_subsequent_administered_dose, i_131_total_administered_dose, primary_neoplasm_focus_type, i_131_total_administered_preparation_technique, person_lifetime_risk_radiation_exposure_indicator, ret_ptc_rearrangement_genotyping_outcome_lab_results_text, genotyping_results_gene_mutation_not_reported_reason, neoplasm_depth, genotype_analysis_performed_indicator, ras_family_gene_genotyping_outcome_lab_results_text, neoplasm_length, neoplasm_width, radiosensitizing_agent_administered_indicator, braf_gene_genotyping_outcome_lab_results_text, lymph_node_preoperative_scan_indicator, radiation_therapy_administered_preparation_technique_text, lymph_node_preoperative_assessment_diagnostic_imaging_type, patient_personal_medical_history_thyroid_gland_disorder_name, first_degree_relative_history_thyroid_gland_carcinoma_diagnosis_relationship_type, radiation_therapy_administered_dose_text, patient_personal_medical_history_thyroid_other_specify_text, primary_thyroid_gland_neoplasm_location_anatomic_site, lymphnodes_examined, zone_of_origin, days_to_bone_scan_performed, diagnostic_mri_performed, diagnostic_mri_result, psa_value, days_to_first_biochemical_recurrence, secondary_pattern, primary_pattern, diagnostic_ct_abd_pelvis_result, bone_scan_results, biochemical_recurrence, tumor_level, gleason_score, number_of_lymphnodes_examined, days_to_psa, tertiary_pattern, diagnostic_ct_abd_pelvis_performed, family_medical_history_relative_family_member_relationship_type, tumor_type, primary_tumor_multiple_present_ind, prior_systemic_therapy_type, melanoma_clark_level_value, melanoma_origin_skin_anatomic_site, malignant_neoplasm_mitotic_count_rate, breslow_depth_value, tumor_tissue_site_1, melanoma_ulceration_indicator, primary_neoplasm_melanoma_dx, new_tumor_dx_prior_submitted_specimen_dx, primary_anatomic_site_count, interferon_90_day_prior_excision_admin_indicator, primary_melanoma_at_diagnosis_count, days_to_submitted_specimen_dx, antireflux_treatment, number_of_relatives_with_stomach_cancer, family_history_of_stomach_cancer, state_province_country_of_procurement, specimen_collection_method_name, child_pugh_classification_grade, hist_of_non_mibc, occupation_primary_job, person_concomitant_prostate_carcinoma_occurrence_indicator, person_concomitant_prostate_carcinoma_pathologic_t_stage, cancer_diagnosis_cancer_type_icd9_text_name, non_mibc_tx, bladder_carcinoma_extracapsular_extension_status, chemical_exposure_text, resp_maint_from_bcg_admin_month_dur, maint_therapy_course_complete, induction_course_complete, person_occupation_years_number, person_primary_industry_text, disease_extracapsular_extension_ind_3, complete_response_observed, diagnosis_subtype, diagnosis_age, mibc_90day_post_resection_bcg, person_occupation_description_text, surgical_procedure_name_other_specify_text, relative_family_cancer_history_ind_3, vascular_tumor_cell_invasion_type, viral_hepatitis_serology, liver_fibrosis_ishak_score_category, ablation_embolization_tx_adjuvant, laboratory_procedure_prothrombin_time_result_value, laboratory_procedure_creatinine_result_lower_limit_of_normal_value, laboratory_procedure_alpha_fetoprotein_outcome_value, laboratory_procedure_alpha_fetoprotein_outcome_upper_limit_of_normal_value, laboratory_procedure_alpha_fetoprotein_outcome_lower_limit_of_normal_value, laboratory_procedure_albumin_result_upper_limit_of_normal_value, laboratory_procedure_albumin_result_specified_value, laboratory_procedure_creatinine_result_upper_limit_of_normal_value, laboratory_prcoedure_platelet_result_upper_limit_of_normal_value, lab_procedure_platelet_result_specified_value, days_to_definitive_surgical_procedure_performed, hematology_serum_creatinine_laboratory_result_value_in_mg_dl, history_hepato_carcinoma_risk_factor, history_hepato_carcinoma_risk_factor_other, cancer_diagnosis_first_degree_relative_number, laboratory_prcoedure_platelet_result_lower_limit_of_normal_value, laboratory_procedure_international_normalization_ratio_result_lower_limit_of_normal_value, laboratory_procedure_albumin_result_lower_limit_of_normal_value, laboratory_procedure_total_bilirubin_result_specified_lower_limit_of_normal_value, laboratory_procedure_total_bilirubin_result_specified_upper_limit_of_normal_value, laboratory_procedure_total_bilirubin_result_upper_limit_normal_value, adjacent_hepatic_tissue_inflammation_extent_type, laboratory_procedure_international_normalization_ratio_result_upper_limit_of_normal_value, mitotic_count, oligonucleotide_primer_pair_laboratory_procedure_performed_name, radiation_type_notes, number_of_successful_pregnancies_which_resulted_in_at_least_1_live_birth, external_beam_radiation_therapy_administered_paraaortic_region_lymph_node_dose, concurrent_chemotherapy_dose, chemotherapy_regimen_type, chemotherapy_negation_radiation_therapy_concurrent_not_administered_reason, postoperative_rx_tx_1, dose_frequency_text, rt_pelvis_administered_total_dose, cervical_neoplasm_pathologic_margin_involved_type, cervical_neoplasm_pathologic_margin_involved_text, cervical_carcinoma_pelvic_extension_text, cervical_carcinoma_corpus_uteri_involvement_indicator, ectopic_pregnancy_count, rt_administered_type, oligonucleotide_primer_pair_laboratory_procedure_performed_text, other_chemotherapy_agent_administration_specify, radiation_therapy_not_administered_reason, patient_pregnancy_therapeutic_abortion_count, days_to_laboratory_procedure_tumor_marker_squamous_cell_carcinoma_antigen_result, days_to_performance_status_assessment, prescribed_dose_units, diagnostic_ct_result_outcome, patient_pregnancy_spontaneous_abortion_count, patient_pregnancy_count, fdg_or_ct_pet_performed_outcome, female_breast_feeding_or_pregnancy_status_indicator, standardized_uptake_value_cervix_uteri_assessment_measurement, pregnant_at_diagnosis, pregnancy_stillbirth_count, patient_history_immune_system_and_related_disorders_text, patient_history_immune_system_and_related_disorders_name, days_to_fdg_or_ct_pet_performed, diagnostic_mri_result_outcome, radiation_therapy_1, radiation_therapy_not_administered_specify, human_papillomavirus_laboratory_procedure_performed_name, chemotherapy_negation_radiation_therapy_concurrent_administered_text, lymph_node_location_positive_pathology_name, keratinizing_squamous_cell_carcinoma_present_indicator, laboratory_procedure_tumor_marker_squamous_cell_carcinoma_antigen_result_value, total_number_of_pregnancies, hysterectomy_Performed_Ind_3, hysterectomy_performed_text, human_papillomavirus_other_type_text, hysterectomy_performed_type, lymphovascular_invasion_indicator, brachytherapy_first_reference_point_administered_total_dose, brachytherapy_method_other_specify_text, lymph_node_location_positive_pathology_text, tumor_response_cdus_type, brachytherapy_method_type, agent_total_dose_count, live_birth_number, human_papillomavirus_laboratory_procedure_performed_text, human_papillomavirus_type, performance_status_assessment_timepoint_category_other_text, ct_scan, new_neoplasm_event_occurrence_anatomic_site, radiologic_tumor_width, contiguous_organ_resection_site, radiologic_tumor_depth, radiologic_tumor_burden, tumor_depth, pathologic_tumor_width, tumor_multifocal, other_contiguous_organ_resection_site, contiguous_organ_invaded, pathologic_tumor_length, pathologic_tumor_depth, pathologic_tumor_burden, radiologic_tumor_length, tumor_total_necrosis_percent, primary_tumor_lower_uterus_segment, days_to_well_differentiated_liposarcoma_resection, metastatic_site_at_diagnosis_other, metastatic_site_at_diagnosis, ss18_ssx_testing_method, ss18_ssx_fusion_status, specific_tumor_total_necrosis_percent, leiomyosarcoma_histologic_subtype, metastatic_neoplasm_confirmed, local_disease_recurrence, days_to_well_differentiated_liposarcoma_primary_dx, mpnst_neurofibromatosis, mpnst_exisiting_plexiform_neurofibroma, mpnst_nf1_genetic_testing, mpnst_specific_mutations, well_differentiated_liposarcoma_primary_dx, leiomyosarcoma_major_vessel_involvement, discontiguous_lesion_count, mpnst_neurofibromatosis_heredity, maximum_tumor_dimension, alcoholic_exposure_category, planned_surgery_status, esophageal_tumor_involvement_site, esophageal_tumor_cental_location, lymph_node_metastasis_radiographic_evidence, days_to_pancreatitis_onset, days_to_diabetes_onset, adenocarcinoma_invasion, surgery_performed_type, columnar_metaplasia_present, relative_cancer_type, amt_alcohol_consumption_per_day, columnar_mucosa_goblet_cell_present, history_of_chronic_pancreatitis, history_of_diabetes, goblet_cells_present, history_of_esophageal_cancer, histologic_grading_tier_category, columnar_mucosa_dysplasia, number_of_relatives_diagnosed, state_province_of_procurement, treatment_prior_to_surgery, initial_diagnosis_by, surgery_performed_type_other, country_of_birth, disease_detected_on_screening, history_pheo_or_para_include_benign, outside_adrenal, history_pheo_or_para_anatomic_site, family_member_relationship_type, post_op_ablation_embolization_tx, days_to_pre_orchi_serum_test, post_orchi_hcg, bilateral_diagnosis_timing_type, post_orchi_ldh, testis_tumor_microextent, undescended_testis_corrected, post_orchi_lh, post_orchi_lymph_node_dissection, post_orchi_testosterone, serum_markers, undescended_testis_corrected_age, undescended_testis_method_left, relation_testicular_cancer, postoperative_tx, testis_tumor_macroextent, synchronous_tumor_histology_pct, pre_orchi_afp, pre_orchi_hcg, pre_orchi_ldh, pre_orchi_lh, pre_orchi_testosterone, synchronous_tumor_histology_type, relative_family_cancer_hx_text, days_to_post_orchi_serum_test, undescended_testis_method_right, testis_tumor_macroextent_other, days_to_bilateral_tumor_dx, level_of_non_descent, post_orchi_afp, intratubular_germ_cell_neoplasm, igcccg_stage, history_of_undescended_testis, molecular_test_result, history_hypospadias, history_fertility, histological_percentage, first_treatment_success, family_history_testicular_cancer, family_history_other_cancer, masaoka_stage, history_myasthenia_gravis, section_myasthenia_gravis, new_neoplasm_occurrence_anatomic_site_text, percent_tumor_sarcomatoid, presence_of_sarcomatoid_features, tmem127, therapeutic_mitotane_lvl_recurrence, therapeutic_mitotane_lvl_macroscopic_residual, therapeutic_mitotane_levels_achieved, metastatic_neoplasm_initial_diagnosis_anatomic_site, mitoses_count, mitotane_therapy, mitotane_therapy_adjuvant_setting, mitotane_therapy_for_macroscopic_residual_disease, mitotic_rate, sinusoid_invasion, therapeutic_mitotane_lvl_progression, excess_adrenal_hormone_diagnosis_method_type, molecular_analysis_performed_indicator, excess_adrenal_hormone_history_type, necrosis, sdhd, sdhc, nuclear_grade_III_IV, sdhb, sdhaf2_sdh5, sdha, atypical_mitotic_figures, ct_scan_findings, ret, cytoplasm_presence_less_than_equal_25_percent, weiss_venous_invasion, weiss_score, vhl, invasion_of_tumor_capsule, diffuse_architecture, serum_mesothelin_lower_limit, asbestos_exposure_type, pleurodesis_performed_90_days, mesothelioma_detection_method, history_asbestos_exposure, pleurodesis_performed_prior, family_history_cancer_type, family_history_cancer_type_other, asbestos_exposure_age, serum_mesothelin_prior_tx, asbestos_exposure_years, serum_mesothelin_upper_limit, asbestos_exposure_source, suv_of_pleura_max, primary_occupation, primary_occupation_years_worked, primary_occupation_other, creatinine_norm_range_lower, creatinine_norm_range_upper, asbestos_exposure_age_last, creatinine_prior_tx, tumor_basal_diameter, tumor_basal_diameter_mx, metastatic_site, tumor_thickness, microvascular_density_mvd, tumor_shape_pathologic_clinical, tumor_infiltrating_lymphocytes, tumor_morphology_percentage, tumor_thickness_measurement, tumor_infiltrating_macrophages, pet_ct_standardized_values, eye_color, other_metastatic_site, extravascular_matrix_patterns, histological_type_1, extranocular_nodule_size, extrascleral_extension, gene_expression_profile, cytogenetic_abnormality, result_of_immunophenotypic_analysis, prior_immunosuppressive_therapy_other, prior_immunosuppressive_therapy_type, prior_infectious_disease, igk_genotype_results_1, immunophenotypic_analysis_method, igk_genotype_results, bone_marrow_biopsy_done, bone_marrow_involvement, bone_marrow_involvement_1, prior_infectious_disease_other, ebv_positive_malignant_cells_percent, b_lymphocyte_genotyping_method_1, prior_immunologic_disease_type, igh_genotype_results_1, b_lymphocyte_genotyping_method, prior_immunologic_disease_other, maximum_tumor_bulk_anatomic_location, immunophenotypic_analysis_results, maximum_tumor_bulk_anatomic_site, immunophenotypic_analysis_test, extranodal_sites_involvement_number, immunophenotypic_analysis_tested, ebv_status_malignant_cells_method, percent_ebv_positive_malignant_cells, tumor_resected_max_dimension, immunophenotypic_analysis_methodology, igh_genotype_results, ebv_diagnostic_methodology, follicular_component_percent, abnormality_tested_methodology, nodal_anatomic_site, histology_of_bone_marrow_sample, abnormality_tested_methodology_1, ldh_upper_limit, number_of_involved_extranodal_sites, extranodal_disease_involvement_site, ebv_antibody_status, extranodal_disease_involvement_site_other, genetic_abnormality_tested_other, genetic_abnormality_tested_1, genetic_abnormality_tested, genetic_abnormality_results_other, genetic_abnormality_results, percentage_of_follicular_component, pet_scan_results, other_genetic_abnormality_tested, epstein_barr_viral_status, lymph_node_involvement_site, mib1_positive_percentage_range, mib1_positive_percentage_range_1, genetic_abnormality_method_other, extranodal_involvment_site_other, ldh_lab_value, hiv_positive_status, ldh_level, ldh_norm_range_upper, abnormality_tested_results_1, abnormality_tested_results, genetic_abnormality_method, bone_marrow_sample_histology, albumin_result_upper_limit, vascular_tumor_cell_type, albumin_result_lower_limit, albumin_result_specified_value, platelet_result_upper_limit, intern_norm_ratio_upper_limit, cholangitis_tissue_evidence, relative_family_cancer_history, platelet_result_lower_limit, hist_hepato_carcinoma_risk, hist_hepato_carc_fact, cancer_first_degree_relative, creatinine_lower_level, prothrombin_time_result_value, ca_19_9_level_upper, ca_19_9_level_lower, ca_19_9_level, creatinine_upper_limit, surgical_procedure_name, creatinine_value_in_mg_dl, bilirubin_lower_limit, total_bilirubin_upper_limit, platelet_result_count, fibrosis_ishak_score, fetoprotein_outcome_value, fetoprotein_outcome_upper_limit, fetoprotein_outcome_lower_limit, inter_norm_ratio_lower_limit, family_cancer_type_txt, bilirubin_upper_limit, days_to_last_known_alive) VALUES ('180A2B9C-9CAC-4D96-86E8-CD6B3B9386B5', 'TCGA-W5-AA2O', 'CHOL', 'MALE', 'Dead', -21118.0, '640', NULL, 0, 57, 'C22.1', 'YES', '8160/3', 'NO', 'No', 'C22.1', 'Bile duct', 'YES', 'NO', 'WHITE', NULL, 'No', NULL, 'NOT HISPANIC OR LATINO', 'YES', 'WITH TUMOR', 'AA2O', 2006, 'Cholangiocarcinoma; intrahepatic', 'W5', '2014-5-23', 'T1', 'M0', '[Not Applicable]', 'N0', '6th', 'Stage I', NULL, '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', 'NO', NULL, NULL, NULL, NULL, NULL, '0', NULL, 'R0', NULL, NULL, NULL, 'G3', '167', '73', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Extended Lobectomy', 'A', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '5.0', 'None', '3.5', '4.1', '450', '1.2', 'None', 'NO', '150', NULL, 'Smoking', NULL, '0.9', '0.8', '55', '0', '34', '1.4', NULL, '1.1', '0.0', '0.3', '150', '0 - No Fibrosis', '3.5', '6.0', '0', '0.8', NULL, '0.4', NULL), ('6E534DD3-81AC-4575-AB1E-02C21E10916D', 'TCGA-W5-AA2X', 'CHOL', 'MALE', 'Dead', -24797.0, '271', NULL, 0, 67, 'C24.0', 'YES', '8160/3', 'NO', 'No', 'C24.0', 'Bile duct', '[Unknown]', 'NO', 'WHITE', NULL, 'No', NULL, 'NOT HISPANIC OR LATINO', 'YES', '[Unknown]', 'AA2X', 2010, 'Cholangiocarcinoma; hilar/perihilar', 'W5', '2014-5-24', 'T2b', 'M1', '[Not Applicable]', 'N1', '7th', 'Stage IVB', NULL, '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', 'NO', NULL, NULL, NULL, NULL, NULL, '0', NULL, 'RX', NULL, NULL, NULL, 'G4', '167', '88', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Pancreaticoduodenectomy (Whipple Resection)', 'A', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Sister', 'NO', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '5.0', 'Micro', '3.5', '4.0', '450', '1.2', 'None', 'YES', '150', NULL, 'No History of Primary Risk Factors', '1', '0.8', '1.0', '55', '0', '203', '1.3', NULL, '0.8', '0.1', '1.0', '541', '1;2 - Portal Fibrosis', '4.0', '6.0', '0', '0.9', 'breast', '0.7', NULL), ('FE57B639-DB7A-460F-ADFE-552F1E034E46', 'TCGA-3X-AAVA', 'CHOL', 'FEMALE', 'Dead', -18303.0, '445', NULL, 0, 50, 'C22.1', 'NO', '8160/3', 'YES', 'No', 'C22.1', 'Bile duct', 'YES', 'NO', 'WHITE', NULL, 'No', NULL, 'NOT HISPANIC OR LATINO', 'YES', 'WITH TUMOR', 'AAVA', 2012, 'Cholangiocarcinoma; intrahepatic', '3X', '2014-9-2', 'T2b', 'M0', '[Not Applicable]', 'NX', '7th', 'Stage II', NULL, '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', 'NO', NULL, NULL, NULL, NULL, NULL, '1', NULL, 'R0', NULL, NULL, NULL, 'G2', NULL, '92', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Segmentectomy; Single', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'NO', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'None', NULL, NULL, '400', NULL, 'None', 'NO', '150', NULL, 'Diabetes mellitus|Smoking', NULL, '0.4', NULL, NULL, NULL, NULL, '1.1', NULL, '0.5', NULL, NULL, '214', '1;2 - Portal Fibrosis', '5.4', '10', '0', NULL, NULL, NULL, NULL), ('779CE92D-1ABD-44FC-9021-EDA4D7F08FFF', 'TCGA-YR-A95A', 'CHOL', 'MALE', 'Dead', -19292.0, '26', NULL, 0, 52, 'C24.0', 'YES', '8160/3', 'NO', 'No', 'C24.0', 'Bile duct', 'YES', 'NO', 'WHITE', NULL, 'No', NULL, '[Not Evaluated]', 'YES', 'WITH TUMOR', 'A95A', 2009, 'Cholangiocarcinoma; hilar/perihilar', 'YR', '2014-10-23', 'T2', 'M1', '[Not Applicable]', 'NX', '6th', 'Stage IV', NULL, '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', 'NO', NULL, NULL, NULL, NULL, NULL, '[Unknown]', NULL, 'R1', NULL, NULL, NULL, 'G2', '177', '77', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'YES', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Segmentectomy; Multiple', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Sister', 'NO', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '4.8', '[Unknown]', '3.4', '4.3', '450000', '1.2', '[Not Evaluated]', 'YES', '125000', NULL, 'No History of Primary Risk Factors', NULL, '0.7', '0.9', '39', '0', '18.15', '1.2', NULL, '0.8', NULL, NULL, '240000', NULL, '1.38', '15', '0', '0', 'Brain tumor', NULL, NULL), ('a43e5f0e-a21f-48d8-97e0-084d413680b7', 'TCGA-FA-8693', 'DLBC', 'MALE', 'Alive', -27468.0, '[Not Applicable]', '132.0', 0, 75, 'C83.3', 'NO', '9680/3', 'YES', 'No', 'C16.9', NULL, 'NO', 'NO', 'WHITE', NULL, 'No', NULL, 'NOT HISPANIC OR LATINO', 'YES', 'TUMOR FREE', '8693', 2012, 'Diffuse large B-cell lymphoma (DLBCL) NOS (any anatomic site nodal or extranodal)', 'FA', '2012-9-12', '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', '[Not Applicable]', '7th', '[Not Applicable]', NULL, 'Stage I', '[Not Applicable]', '[Not Applicable]', 'YES', NULL, '[Not Applicable]', NULL, NULL, NULL, NULL, '[Unknown]', NULL, NULL, NULL, NULL, NULL, NULL, '169.0', '82.0', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '[Unknown]', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Negative|Positive|Negative|Negative', NULL, 'None', NULL, NULL, NULL, 'Not Tested', NULL, NULL, NULL, NULL, NULL, NULL, '[Unknown]', NULL, NULL, NULL, NULL, NULL, NULL, 'CD 10> 30%|CD20|CD5|Cyclin D1', NULL, NULL, NULL, NULL, NULL, 'Immunohistochemistry|Immunohistochemistry|Immunohistochemistry|Immunohistochemistry', 'Not Tested', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '1', 'Stomach', '[Not Evaluated]', NULL, NULL, NULL, NULL, NULL, NULL, '< or = 10%', NULL, NULL, NULL, NULL, '51 - 75%', NULL, NULL, NULL, NULL, 'negative', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);